
Other information as needed to protect confidentiality of Takeda or partners, personal
information, or to otherwise protect 
the integrity of the clinical study.Title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, 
3-Period, Incomplete Block Design Study to Investigate the Safety, Tolerability,
Pharmacokinetics and Pharmacodynamics of TAK-954 in Healthy Adult Participants.
Study ID: [REMOVED]
Protocol Approve Date: 11 March 2019
Certain information  within this Statistical Analysis Plan has been  r edacted (ie, specific content is masked 
irreversibly from view with a black/blue bar) to protect either personally identifiable (PPD) information 
or company confidential information (CCI)
. 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
TITLE PAGE
TAKEDA PHARMACEUTICALS
PROTOCOL
A Phase 1, Randomized, Double -Blind, Placebo -Controlled, Single Ascending Dose, 
3-Period, Incomplete Block Design Study to Investigate the Safety, Tolerability,
Pharmacokinetics and Pharmacodynamics of TAK -954 in Healthy Adult Participant s.
Study Identifier : TAK-954-1009
Compound: TAK-954
Date: 11March 2019
Version/Amendment 
Number:Amendment 01
Amendment History : 
Date Amendment Number Amendment Ty pe Region
07 February 2019 Initial Versi on
11 March 2019 01 Not Applicable United States
Propert non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 2of 88
Protocol Incorporating Amendment No. 01 11 March 2019
TABLE OF CONTENTS
1.0 STUDY SUMMARY ...................................................................................................... 7
2.0 STUDY SCHEMATIC .................................................................................................. 13
3.0 SCHEDULE OF STUDY PR OCEDURES .................................................................... 15
3.1 Screening and Period 1 ............................................................................................ 15
3.2 Periods 2 and 3 ........................................................................................................ 18
4.0 INTRODUCTION ......................................................................................................... 21
4.1 Background ............................................................................................................. 21
4.2 Rationale for the Proposed Study ............................................................................. 22
4.3 Benefit/Risk Profile .................................................................................................22
5.0 STUDY OBJECTIVES AND ENDPOINTS .................................................................. 23
5.1 Hypothesis ............................................................................................................... 23
5.2 Study  Objectives ...................................................................................................... 23
5.2.1 Study  Primary  Object ives............................................................................ 23
5.2.2 Study  Secondary  Object ive......................................................................... 23
5.2.3 Study  Expl oratory  Object ives...................................................................... 23
5.3 Endpoints ................................................................................................................. 23
5.3.1 Primary Endpo ints....................................................................................... 23
5.3.2 Secondary  Endpo ints................................................................................... 24
5.3.3 Exploratory  Endpo ints................................................................................. 24
6.0 STUDY DESIGN AND DES CRIPTION ....................................................................... 26
6.1 Study  Design ........................................................................................................... 26
6.2 Dose Escal ation....................................................................................................... 27
6.3 Rationale for Study  Design, Dose, and Endpoints .................................................... 27
6.3.1 Rationale of Study  Design ........................................................................... 27
6.3.2 Rationale for Dose ...................................................................................... 28
6.3.2.1 Starti ng Dose for This Study ................................................................... 28
6.3.2.2 Maximum Dose/Exposure for This Study ............................................... 28
6.3.3 Rationale for Endpoints ............................................................................... 29
6.3.3.1 Safety Endpo ints.................................................................................... 29
6.3.3.2 Pharmacokinet ic Endpo ints.................................................................... 29
6.3.3.3 Pharmacodynamic Endpo ints.................................................................. 29
6.3.4 Future Bio medical Research ........................................................................ 29
6.3.5 Critical Procedures Based on Study  Object ives: Timing of Procedures ........ 30
6.4 Study  Design/Dosing/Procedures Modificat ions Permitted Within Protocol 
Param eters ............................................................................................................... 30
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 3of 88
Protocol Incorporating Amendment No. 01 11 March 2019
6.5 Study  Beginning and End/Co mpletion..................................................................... 30
6.5.1 Definit ion of Beginning o f the Study ........................................................... 30
6.5.2 Definit ion of End of the Study ..................................................................... 30
6.5.3 Definit ion of Study  Com pletion.................................................................. 30
6.5.4 Definit ion of Study  Discont inuat ion............................................................ 30
6.5.5 Criteria for Premature Terminat ion or Suspension of the Study ................... 31
6.5.6 Criteria for Premature Terminat ion or Suspension of a Site ......................... 31
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF PARTICIPANTS .....32
7.1 Inclusio n Cri teria..................................................................................................... 32
7.2 Exclusio n Cri teria.................................................................................................... 32
7.3 Excluded Med ications, Supplements, Dietary  Products ............................................ 34
7.4 Diet, Fl uid, Act ivity.................................................................................................35
7.4.1 Diet and Fluid ............................................................................................. 35
7.4.2 Activity....................................................................................................... 35
7.5 Criteria for Di scont inuation or Withdrawal o f a Parti cipant ...................................... 35
7.6 Procedures for Discont inuat ion or Withdrawal o f a Parti cipant ................................ 36
7.7 Parti cipant Replacement .......................................................................................... 36
8.0 CLINICAL STUDY MATER IAL MANAGEMENT ..................................................... 37
8.1 Clinical Study  Drug .................................................................................................37
8.1.1 Clinical Study Drug Labeling ...................................................................... 37
8.1.2 Clinical Study  Drug Inventory  and Storage ................................................. 37
8.1.3 Clinical Study  Drug Blinding ...................................................................... 37
8.1.4 Randomization Code Creation and Storage ................................................. 37
8.1.5 Clinical Study  Blind Maintenance/Unblinding Procedure ............................ 38
8.1.6 Accountabilit y and Destruction of Sponsor -Supplied Drugs ........................ 38
9.0 STUDY PROCEDURES ............................................................................................... 39
9.1 Administrative Procedures ....................................................................................... 39
9.1.1 Informed Consent Procedure ....................................................................... 39
9.1.1.1 Assignment of Screening and Rando mizat ion Numbers .......................... 39
9.1.1.2 Study  Drug Assignment .......................................................................... 39
9.1.2 Inclusio n and Exclusio n.............................................................................. 39
9.1.3 Medical  History /Dem ography ..................................................................... 40
9.1.4 Concomitant Medications ............................................................................ 40
9.2 Clinical Procedures and Assessments ....................................................................... 40
9.2.1 Physical Examinat ion.................................................................................. 40
9.2.2 Heightand Weight ...................................................................................... 40
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 4of 88
Protocol Incorporating Amendment No. 01 11 March 2019
9.2.3 BMI ............................................................................................................ 40
9.2.4 Vital Signs .................................................................................................. 40
9.2.5 12-Lead ECG ................................ .............................................................. 41
9.2.6 Study  Drug Administration ......................................................................... 41
9.2.7 AE Monitoring ............................................................................................ 41
9.2.8 Laboratory  Procedures and Assessments ..................................................... 42
9.2.8.1 Clinical Laboratory  Tests ........................................................................ 42
9.3 PK, PD, and Bio markers Samples ............................................................................ 43
9.3.1 PK Measurements ....................................................................................... 43
9.3.1.1 Plasma for PK Measurements .................................................................44
9.3.1.2 Urine for PK Measurements ................................................................... 45
9.3.2 PD Measurements ....................................................................................... 45
9.3.3 Biomarkers Measurements .......................................................................... 45
9.3.4 Confinement ............................................................................................... 46
10.0 ADVERSE EVENTS .................................................................................................... 47
10.1 Definit ions and El ements of AEs ............................................................................. 47
10.1.1 SAEs ........................................................................................................... 49
10.1.2 Speci al Interest AEs .................................................................................... 50
10.2 AE Pr ocedures ......................................................................................................... 50
10.2.1 Assigning Severit y/Intensit y of AEs ............................................................ 50
10.2.2 Assigning Causalit y of AEs ......................................................................... 51
10.2.3 Start Date .................................................................................................... 51
10.2.4 End Date ..................................................................................................... 51
10.2.5 Pattern of Adverse Event (Frequency) ......................................................... 51
10.2.6 Action Taken Wit h Study  Treatm ent........................................................... 51
10.2.7 Outcom e..................................................................................................... 52
10.2.8 Collect ion and Reporti ng of AEs, SAEs, Special Interest AEs, and 
Abnorm al LFTs ........................................................................................... 52
10.2.8.1 Collect ion Peri od.................................................................................... 52
10.2.8.2 Reporting AEs ........................................................................................ 52
10.2.8.3 Reporting SAEs ...................................................................................... 53
10.2.8.4 Reporting Special  Interest AEs ............................................................... 54
10.2.8.5 Reporting of Abnormal LFTs .................................................................54
10.2.9 Safety Reporting to Invest igators, IRBs or IECs, and Regulatory  
Authori ties.................................................................................................. 54
11.0 STATISTICAL METHODS ................................ .......................................................... 55
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 5of 88
Protocol Incorporating Amendment No. 01 11 March 2019
11.1 Statistical and Analyt ical Plans ................................................................................ 55
11.1.1 Analysis Sets ............................................................................................... 55
11.1.1.1 Safety Set............................................................................................... 55
11.1.1.2 PK Set .................................................................................................... 55
11.1.1.3 PD Set .................................................................................................... 55
11.1.2 Analysis of Demography  and Other Baseline Characterist ics....................... 55
11.1.3 Safety Analysis ........................................................................................... 55
11.1.3.1 AEs ........................................................................................................ 56
11.1.3.2 Clinical Laboratory  Evaluat ion............................................................... 56
11.1.3.3 Vital Signs.............................................................................................. 56
11.1.3.4 ECGs ...................................................................................................... 56
11.1.3.5 Other Safet y Param eters ......................................................................... 56
11.1.4 PK Analysis ................................................................................................ 56
11.1.5 PD Analysis ................................................................................................ 56
11.2 Interim Analysis and Criteria for Early Terminat ion................................................ 57
11.3 Determinat ion of Sample Size .................................................................................. 57
12.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 58
12.1 Study -Site Moni toring Visit s................................................................................... 58
12.2 Protocol  Deviat ions.................................................................................................. 58
12.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 58
13.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 59
13.1 IRB and/or IEC Approval ........................................................................................ 59
13.2 Parti cipant Inform ation, Inform ed Consent, and Participant Authorizat ion............... 60
13.3 Parti cipant Confident iality....................................................................................... 61
13.4 Publicat ion, Di sclosure, and Clinical Study  Registrati on Policy ............................... 61
13.4.1 Publicat ion and Disclosure .......................................................................... 61
13.4.2 Clinical Study  Registrati on.......................................................................... 62
13.4.3 Clinical Study  Resul ts Discl osure................................................................ 62
13.5 Insurance and Co mpensation for Injury .................................................................... 62
14.0 ADMINISTRATIVE AND R EFERENCE INFORMATION ......................................... 63
14.1 Administrative Informat ion...................................................................................... 63
14.1.1 Study  Contact Informat ion.......................................................................... 63
14.1.2 Invest igator Agreement ............................................................................... 64
14.1.3 Study -Related Responsibilit ies.................................................................... 65
14.1.4 Protocol  Amendment 01 Summary  of Changes ........................................... 65
14.1.5 List of Abbreviat ions................................................................................... 65
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 6of 88
Protocol Incorporating Amendment No. 01 11 March 2019
15.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 68
15.1 CRFs (El ectronic and/or Paper) ................................................................................ 68
15.2 Record Retention ..................................................................................................... 68
16.0 REFERENCES .............................................................................................................. 70
17.0 APPENDICES ............................................................................................................... 71
LIST OF IN -TEXT TABLES
Table 6.a Planned TAK -954 and Pl acebo Doses ................................................................ 27
Table 6.b Mean (SD) Actual and Predicted Exposure Parameters for TAK -954 after Oral 
and IV dosing ..................................................................................................... 29
Table 7.a Excluded Medicat ions, Supplements, and Dietary  Products ................................ 34
Table 9.a Sequence Groups ............................................................................................... 39
Table 9.b Primary Specimen Collections ........................................................................... 43
Table 9.c Pharmacokinet ics Sample Co llection Time Window .......................................... 44
Table 10.a Takeda Medi cally Si gnificant AE List ................................................................ 50
LIST OF IN -TEXT FIGURES
Figure 2.a Schemat ic of Study  Design ................................................................................ 14
LIST OF APPENDICES
Appendix A Responsibilit ies o f the Invest igator ..................................................................... 72
Appendix B Elements of the Participant Informed Consent .................................................... 74
Appendix C Invest igator Consent to the Use of Personal Information .................................... 77
Appendix DPregnancy and Contraception ............................................................................. 78
Appendix E Detailed Descript ion of Amendments to Text ..................................................... 81
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK-954
Study ID TAK-954-1009 Page 7 of 88Protocol Incorporating Amendment No. 01 11 March 2019
1.0 STUDY SUMMARY
Name of Sponsor:
Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of 
Takeda Pharmaceutical Company, Ltd40 Landsdowne StreetCambridge, Massachusetts USA 02139Telephone: +1 (617) 679-7000Compound:
TAK-954
Study Identifier: TAK-954-1009 Phase: 1
Protocol Title: A Phase 1, Randomized, Double-Blind, Placebo- Controlled, Single Ascending Dose, 3-Period, 
Incomplete Block Design Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-954 in Healthy Adult Participants.
Study Design:
This is a double-blind, placebo-controlled, single ascending intravenous (IV) dose, 3-period, incomplete block design 
study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TAK-954 at higher IV doses than those previously studied. In this Phase 1 study, healthy adult participants will attend a screening visit within 28 days prior to the first dose.
Participants will be randomized to one of 3 treatment sequences as detailed in the table below. In each sequence, each 
participant will receive 2 doses of the active drug (out of 3 evaluated dose levels) in an ascending order and 1 dose of placebo. A sample size of 6 participants is proposed based on empirical considerations.
Period 1 Period 2 Period 3
SequenceDay 1
(Lead-in)Day 2
(Treatment)Day 1
(Lead-in)Day 2
(Treatment)Day 1
(Lead-in)Day 2
(Treatment)
Sequence 1 (n=2)Placebo Placebo TAK-954 Treatme nt B TAK-954 Treatment C
Sequence 2 
(n=2)TAK-954 Treatment A Placebo Placebo TAK-954 Treatment C
Sequence 3 
(n=2)TAK-954 Treatment A TAK-954 Treatment B Placebo Placebo
Lead-in TAK-954: 0.1 mg TAK-954 IV infusion.
Treatment A: 0.5 mg TAK-954 IV infusion.
Treatment B: 1 mg TAK-954 IV infusion.
Treatment C: 2 mg TAK-954 IV infusion.
On Day 1 of each period, each participant will receive a lead-in dose of 0.1 mg TAK-954 (if scheduled to receive a dose of active drug on Day 2 of that period as per the randomization schedule) or placebo (if scheduled to receive a placebo on Day 2 of that period as per the randomization schedule) as a 60 minutes IV infusion. On Day 2 of each period, participants will receive either a single dose of 0.5 mg, 1 mg, or 2 mg TAK-954 or placebo as a 60-minute infusion as per the randomization schedule.
Safety will be assessed by monitoring for adverse events (AEs), vital signs, orthostatic vital signs, electrocardiograms 
(ECGs), safety laboratory assessments, and physical examinations throughout each dosing period. Blood (for plasma) samples for assessment of TAK-954 concentrations will be co llected at selected times from predose t hrough to 9 hours 
after each lead-in dose (Day 1). Blood (for plasma) samples for assessment of TAK-954 concentrations will also be collected at selected times from predose through 336 hours (Day 16) after each Day 2 dose. Urine samples for assessment of TAK-954 concentrations will also be collected at selected times from predose through 36 hours (Day 3) after each Day 2 dose. . The time to first stool will be recorded following dosing on Day 1 until prior to dosing on Day 2 and following dosing on Day 2. The number 
of stools per day and stool form (Bristol Stool Form Scale) will be recorded following dosing on Day 1 until prior to dosing on Day 2, and for 36 hours following Day 2 dosing.
Property of Takeda: For nperiod, period e
drug on Dug on 
Day 2 of tay 2 of
articipanticipan
on as per tn as per
fety will bfety wil
(ECGs), ECGsr non-commercial use only and subject to the applicable Terms of Usemsms
ble
Dose, 3ose, 3 -PeP
PharmacPharmaca
-period, period
odynamicdynam
adult partiult par
iled in theed in th
d dose levd dose le
pirical coirical cea
eriod 2riod 2nd
1
add--in)in)yayayaya
TAKAK-9549o
l A Plllual
tment Aent Arc
K-954 IV 954 IV
54 IV in4 IV i
954 IV in54 IV 
AKK-954 IV954 mm
samplesam
aftern
yty
CCI
TAK-954
Study ID TAK-954-1009 Page 8 of 88Protocol Incorporating Amendment No. 01 11 March 2019
The last dose in the previous period and the first dose of the next period will be separated by a minimum of 16 days.
The starting dose of TAK-954 on Day 2 (Period 1) will be 0.5 mg, which is the highest dose previously used in a 
completed study following IV administration. Subsequent doses will be chosen based on emerging data; the currently proposed doses are 1 mg and 2 mg. Dose escalation to the next dose level (ie, next period) will not take place until the Investigator and the Sponsor have determined that adequate safety/tolerability from the previous period has been 
demonstrated to permit proceeding to the next dose level. Additional cohort(s) (approximately 6 participants per 
cohort) may be enrolled if it is deemed appropriate by the Investigator and the Sponsor to repeat a dose level or to study an interim dose level (lower than those planned) in a new cohort.
Day 16 of Period 3 will also be considered as the follow-up visit for participants who complete the study. All 
participants who received at least 1 dose of study drug or placebo and withdraw from the study early will return for a follow-up visit, 10-14 days af ter the last dose administration.
Study Primary Objectives:
!To evaluate the safety and tolerability of single ascending IV doses of TAK-954.
!To evaluate the PK of single ascending IV doses of TAK-954.
Secondary Objective:
!To evaluate the PD effect of single ascending IV doses of TAK-954 on the gastrointes tinal (GI) motility in healthy 
participants while in confinement.
Study Participant Population: Healthy male and female par ticipants aged 18 to 55 years inclusive. Body Mass Index 
(BMI) 18.0-32.0 kg/m2, inclusive, body weight ≥50 kg. 
Planned Number of Participants:
6
Additional cohort(s) (approximately 6 participants per 
cohort) may be enrolled if it is deemed appropriate by 
the Investigator and the Sponsor to repeat a dose level 
or to study an interim dose level (lower than those planned) in a new cohort.Planned Number of Sites:
1
Dose Levels:
Day 1 (Lead-in):0.1 mg TAK-954 (100 mL x 0.001 mg/mL TAK-954 
solution for IV administration)
Placebo will be administered as 100 ml saline solution 
for IV infusion
Lead-in treatment (ie, TAK-954 or placebo) will match 
the scheduled treatment (TAK-954 or placebo) to be received on Day 2 of that period as per the randomization schedule.Route of Administration:
IV
Property of Takeda: For non-co00 mL x 0 mL x
ministratiministra
e adminisadmin
ionion
treatmenreatm
cheduled hedule
ceived onceived o
randomiandomommercial use onl ject to the applicable Terms of Usehe e 
n
per per 
vel or to or t
study. Alldy. A
arly will rrly willmsms
the gastrohe gastpp
participaparti
g. 
cipants pipants
ppropriatpropria
peat a doseat a d
ower thanwer thPleeoeoeo
o
oofCCICCI
TAK -954
Study ID TAK -954-1009 Page 9of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Day 2 (Treatment):
Treatment A: 
0.5 mg TAK -954 (100 mL x 0.005 mg/mL TAK -954 
solution for IV administration)
Treatment B: 
1 mg * TAK -954 (100 mL x 0.01 mg/mL TAK -954 
solution for IV administr ation)
Treatment C: 
2 mg * TAK -954 (100 mL x 0.02 mg/mL TAK -954 
solution for IV administration)
Placebo will be administered as 100 ml saline solution 
for IV infusion.
* Dose levels may be changed based on emerging data
Duration of Treatment:
On Day 1 of each period, each participant will receive a 
lead-in dose of 0.1 mg TAK -954 o r placebo as a 
60-min uteIV infusion. On Day 2 of each period, 
participants will receive a single dose of either 
TAK -
954 (if received the lead -in dose of TAK -954 on 
Day 1 of th at period) or placebo (if received placebo on 
Day 1 of that period) as a 60-minute infusion.Planned Study Duration:
Approximately 73 days including screening period and 
follow -up visit.
Criteria for Inclusion:
In order to be eligible for study participat ion, participants must: 
1.Healthy , adult, male or female, 18 -55years of age, inclusive, at screening. 
2.Body mass index (BMI) ≥18 and ≤ 32.0 kg/m2, weighing ≥50 kg at screening. 
3.Medically healthy with no clinically significant medical histor y, physical examination, laboratory profiles, vital 
signs, orthostatic vital signs, or ECGs, as deemed by the Investigator or designee.
4.Continuous nonsmoker who has not used nicotine -containing -products for at least 3 months prior to the first dose 
and throughout th e study based on participant self -reporting.
5.For a male or female of childbearing potential, use an acceptable birth control methods as indicated in 
Appendix D.
6.Understands the study procedures in the informed consent form (ICF) and be willing and able to comply with the 
protocol.
Criteria for Exclusion:
The participant must be excluded from participating in the study if the participant: 
1.Is mentally or lega lly incapacitated or has significant emotional problems at the time of the screening visit or 
expected during the conduct of the study.
2.Histor y or presence of clinically significant medical or psychiatric condition or disease in the opinion of the 
Investigator or designee.
3.Histor y of any  illness that, in the opinion of the Investigator or designee, might confound the results of the study 
or poses an additional risk to the participant by their participation in the study.
4.Histor y or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.
5.Histor y or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds.
6.Histor y or presence of:
risk factors for Torsade de Pointes (eg, heart failure, unexplained syncope, cardiomyopathy, or family 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 10of 88
Protocol Incorporating Amendment No. 01 11 March 2019
history  of Long QT Syndrome);
family  history  of sudden death;
sick sinus syndrome, second or third degree atrioventricular (AV) block, myocardial infarct ion, pulmonary 
congestion, symptomatic or significant cardiac arrhythmia, prolonged heart rate corrected QT interval by 
Fredericia (QTcF) interval, or conduction abnormalities;
cholecystectomy;
orthostatic hypotension or orthostatic vital sign results at s creening with a decrease in systolic >20 mmHg or 
decrease in diastolic >10 mmHg, and increase in pulse of >20 bpm.
7.Female participants with a positive pregnancy test or who are lactating.
8.Positive urine drug or alcohol results at screening or first check in-.
9.Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or 
hepatitis C virus (HCV).
10.Seated blood pressure is less than 100/60 mmHg or greater than 140/90 mmHg at screening.
11.QTcF interval is >450 msec (m ales and females) or has ECG findings deemed abnormal with clinical significance 
by the Investigator or designee at screening or first check -in, including:
T wave forms which make accurate QT measurement difficult;
Absence of regular atrial or the presence of junctional rhythm;
Abnormal sinus rhythm (heart rate <55 bpm or >100 bpm);
PR interval >210 msec, or QRS complex >110 msec.
12.Unable to refrain from or anticipates the use of:
Any drug, including prescription and non-prescription medications, herbal reme dies, or vitamin supplements 
beginning 14 days prior to the first dosing and throughout the study. After randomization, acetaminophen 
(up to 2 g per 24 hours) may be administered at the discretion of the Investigator or designee. Acceptable 
birth control m ethods as described in Appendix Dwill be allowed.
Any drugs known to be significant inducers of Cytochrome P450 (CYP) 3A4 enzymes and/or P -gp, 
including St . John’s Wort, for 28 days prior to the first dosing and throughout the study. 
Serotonin antagonists, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, serotonin and 
norepinephrine reuptake inhibitors, gamma -aminobutyric acid antagoni sts, and N -methy l-D-aspartate 
receptor antagonists for 14 days prior to the first dosing and throughout the study.
Serotonin agonists for 28 days prio r to the first dosing and throughout the study.
Appropriate sources (eg, Flockhart Table™) will be consulted to confirm lack of PK/PD interaction with study 
drug.
13.Participant has infrequent bowel movements (less than approximately once per day) within 30 days prior to first 
dosing.
14.Recent history of abnormal bowel movements, such as diarrhea, loose stoo ls, or constipation, within 2 weeks of 
first dosing.
15.Has been on a diet incompatible with the on study -diet, in the opinion of the Investigator or designee, within the 
30days prior to the first dosing and throughout the study.
16.Donation of blood or signif icant blood loss within 56 days prior to the first dosing.
17.Plasma do nation within 7 days prior to the first dosing.
18.Participation in another clinical study within 30 days prior to the first dosing. The 30 -day window will be derived 
from the date of the las t blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 
of the current study.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK-954
Study ID TAK-954-1009 Page 11 of 88Protocol Incorporating Amendment No. 01 11 March 2019
Main Criteria for Evaluation and Analyses:
The primary endpoints of the study are:The following safety parameters of TAK-954 derived after a single dose of TAK-954 on Day 2 of each treatment 
period:
!Treatment emergent AE (TEAE) assessments.
!Vital signs.
!12-lead ECG.
!Clinical laboratory testing (hematology, serum chemistry and urinalysis).
The following plasma PK parameters of TAK-954 derived after a single dose of TAK-954 on Day 2 of each treatment 
period:
!AUC
0-t: Area under the plasma concentration-time curve from time 0 to time of the last quantifiable 
concentration.
!AUC 0-inf: Area under the plasma concentration-time curve from time 0 to infinity.
!Ceoi: Observed plasma concentration at the end of infusion.
!CL: Clearance.
!Vz: Volume of distribution.
The following urine PK parameters of TAK-954 derived after a single dose of TAK-954 on Day 2 of each treatment 
period
!Ae: Amount of drug excreted in urine.
!fe: Fraction of IV dose excreted in urine.
!CLR: Renal clearance.
The secondary endpoints will be assessed through evaluation of the following parameters: The following PD parameters derived after a single dose of TAK-954 on Day 2 of each treatment period
!Time to first stool.
!Number of stools per day.
!Stool form (Bristol Stool Form Scale).
The exploratory endpoints will be assessed through evaluation of the following parameters:
Properttmmercial use only and subject to the applicable Termsay 2 of eay 2 of e
last quantst quant
nity.nity.
gle dose gle dos
h evaluatievalua
single dongle d
m Scale).Scale
assesassms of Usemsms
CCICCI
TAK-954
Study ID TAK-954-1009 Page 12 of 88Protocol Incorporating Amendment No. 01 11 March 2019
Statistical Considerations:
Safety:Quantitative safety data as well as the difference to baseline, when appropriate, will be summarized using the 
appropriate descriptive statistics.
Pharmacokinetics:
Individual TAK-954  plasma and urine concentration data, as appropriate, and PK parameters will be 
listed by participant and treatment, and summarized by treatment (TAK-954 plasma concentrations and PK parameters) and nominal time (TAK-954 plasma concentrations).
Statistical analyses of additional plasma PK parameters may be performed, if appropriate.
Dose proportionality will be assessed graphically.
Pharmacodynamics:Time to first stool, number of stools per day, and stool consistency (form) will be reported using descriptive and 
summary statistics.
Sample Size Justification: 
Approximately 6 participants will be enrolled in this study. This sample size is based on empirical considerations and 
is considered adequate for the objectives of this study.
Property of Takeda: For non-commercial use only and subjubjbject to the applicable Terms of Useers will bes will b
PK PK 
rted usingrted usmsms
is based os basedo
bjCCI
TAK -954
Study ID TAK -954-1009 Page 13of 88
Protocol Incorporating Amendment No. 01 11 March 2019
2.0 STUDY SCHEMATIC
Pretreatment Treatment Periods 1 -3
Study Exit (a) Follow Up (b) ScreeningCheck -in and 
Predose 
AssessmentsLead -in Dose and 
Study AssessmentsTreatment Dosing 
and Study 
AssessmentsSafety and PK 
Assessments
Within 28days prior 
to first dosingDay -1 Day 1 Day 2 Day 3 Days 4 -16 Day 16 of 
Treatment 
Period 314 days after last 
dose
Outpatient Visit Confinement (a) (c) Outpatient Visits (c)
(a)At all times, a participant may be required to remain at the clinical research unit for longer at the discretion of the Investigator or designee.
(b)Day 16 of Period 3 will also be considered as the follow -up visit for participants w ho complete the study. All participants who received at least 1 dose of study 
drug o r placebo and withdraw from the study early will return for a follow -up visit 10 -14 days after the last dose administration.
(c)Participant s will start the confinement on Day -1 and be released from confinement after Day 3 study assessments are complete and will return to the study site 
for subsequent safety and PK assessments as per the scheduled of study procedures (Section 3.0); There will be a washout period of at least 1 6days between the 
last dose in the previous period and the first dose of the next period .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 14of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Figure 2.a Schematic of Study Design
TAK -954/
PlaceboTAK -954 
PK
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 15of 88
Protocol Incorporating Amendment No. 01 11 March 2019
3.0 SCHEDULE OF STUDY PROCEDURES
3.1 Screening and Period 1
Screening aStudy Period 1 b
Day
-1Day
1Day
2Day
3
Hours relative to start of infusion on Day 1 Hours relative to start of infusion on Day 2
Check -in Predose 0 1 1.083 1.25 3 9 Predose 0 0.5 1 2 4612 24 36
Administrative Procedures
Informed Consent (including Future 
Biomedical Research)X
Inclusion/Exclusion Criteria X
Medical History X
Prior/Concomitant Medication Review X------------------------ ------- -------- --------------- Continuous --------- ---------------- ---------------------------------------------------- X
Clinic Procedures/Assessments
Full Physical Examination X
Abbreviated Physical Examination X X
Height X
Weight X X
12-Lead ECG X X X X X X X X X X
Orthostatic Vital Signs (HR, BP) X X X X X X X X X
Vital Signs (HR, BP) X
Vital signs (RR and T) X X X X
TAK -954 / Placebo Administration X X
Adverse Events Monitoring X-------------------------------------------- -------------- Continuous -------- ------- ----------- ------------------ --------------------------------- X
Laboratory Procedures/Assessments
Hematology, Chemistry c, Urinalysis X X X X
Serum FSH -if applicable X
Urine Drug Screen X X
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK-954
Study ID TAK-954-1009 Page 16 of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Screening  aStudy Period 1  b
Day
-1Day
1Day
2Day
3
Hours relative to start of infusion on Day 1 Hours relative to start of infusion on Day 2
Check-in Predose 0 1 1.083 1.25 3 9 Predose 0 0.5 1 2 4 6 12 24 36
Urine Alcohol Screen X X
HIV/Hepatitis Screen X
Blood for DNA analysis (optional) Xd
Serum Pregnancy Test (hCG) – Female 
Participants OnlyXX
Pharmacokinetic Evaluations
Blood for Plasma TAK-954 (  
)XX  eXX X X X X X  eXX XX XX
Urine for Urin ary TAK-954  X------------------------------------------------- Continuous  f------------- ------------------------------------X
Pharmacodynamic Evaluations
Time to Onset of Defecation X-------------- Con tinuous --- ---------- X X  --------------- Conti nuous -------------- X
Number of Stools per Day X-------------- Conti nuous ------------- X X  --------------- Continuous -------------- X
Stool Form (Bristol Stool Form Scale) X-------------- Continuous ------------- X X  --------------- Conti nuous -------------- X
Other
Confinement X---------------------------------------- --------------- Continuous  ------------ ------------------------------------- ---------X
Visit and Return Visits X
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Usele abica
HoursHourap
PredosePredoetttthottooo
cto
ctctct
bjct
bjbjbjebj
dnddsd ssdXXnddd
yd
------------------lyyy
uuuse useeooo
uuuusualciememmmemeeeeme XX----------mmmm
om-cC
CI
CCI
TAK-954
Study ID TAK-954-1009 Page 17 of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Study Period 1
Day 8 Day 10 Day 12 Day 14 Day 16
Hours relative to start of infusion on Day 2
144 192 240 288 336
Administrative Procedures
Prior/Concomitant Medication Rev iew X---------------------------- -------------- Continuous  --------- ----------------------------- ---------X
Clinic Procedures/Assessments
12-Lead ECG X X X X
Orthostatic Vital Signs (HR, BP) X X X X
Adverse Events Monitoring X ------------------------------------------ Conti nuous -------------- ---------------------------------X
Pharmacokinetic Evaluations
Blood for Plasma TAK- 954  XXXXX
Other
Visit and Return Visits X X X X X
a. Within 28 days prior to the first study drug administration. 
b. There will be a washout period of at least 16 days between the last dose in the previous period and the first dose of the nex t period.
c. Serum chemistry tests will be performed after at least an 8-hour fast; however, in case of dropouts or rechecks, participants  may not have fasted for 8 hours 
prior to the serum chemistry sample is taken.
d. DNA sample should be obtained after dosing (or with the next scheduled blood draw) on randomized participants only.
e. To be performed at the end of infusion.
f. Urine will be collected at predose (spot sample) and from 0-12, and 12-24 hours postdose on Day 1 and from 0-12, 12-24, and 24- 36 hours on Day 2.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Usele abiiicapli infusion onfusionpppp
0ap
thehe
ContinuouContinuot
ct tott oeeecjebjejejej
---------------su
and d
XXan
ooononly lyoooono
ast dose ist dose
our r ofast; fast; h
h the next he nex
e) and froand freCCI
TAK-954
Study ID TAK-954-1009 Page 18 of 88
Protocol Incorporating Amendment No. 01 11 March 2019
3.2 Periods 2 and 3
Study Periods 2 and 3  a
Day
-1Day 1 Day 2 Day 3
Hours relative to start of infusion on Day 1 Hours relative to start of infusion on Day 2
Check-in Predose 0 1 1.083 1.25 3 9 Predose 0 0.5 1 2 4 6 12 24 36
Administrative Procedures
Prior/Concomitant Medication Review X------------------------------------------------------- Continuous ------------------------- ------------------------------------------------X
Clinic Procedures/Assessments
Abbreviated Physical Examination X X
Weight X X
12-Lead ECG X X X X X X X X X
Orthostatic Vital Signs (HR, BP) X X X X X X X X
Vital Signs (HR, BP) X
Vital signs (RR and T) X X X
TAK-954 / Placebo Administration X X
Adverse Events Monitoring X----------------------------------------------------------- Con tinuous ----------------- -------------- ---------------------------------X
Laboratory Procedures/Assessments
Hematology, Chemistry  b, Urinalysis X X X
Urine Drug Screen X
Urine Alcohol Screen X
Serum Pregnancy Test (hCG) – Female 
Participants OnlyX
Pharmacokinetic Evaluations
Blood for Plasma TAK-954  
)XX  cXX X X X X X  cXX X XX X
Urine for Urinary TAK-954  
)X---------------------------------------------------- Continuousd------------ ---------------------------------------------X
Property of Tak  For nFoFFonon-commercial use only and subject to the applicable Terms of Usele 
ppa
HheotProtototot
ect ttt
uous ous ------ec
subsuububjbbbjsubsusuu
dsu
ndndndndaylyyyy
oneseeee
XXus
----------------ial
ercmerercrcrcrcrcercmeeee
mmcococococo
XXn-
For nrn
FoFoFoFoFo
akCCI
CCI
TAK -954
Study ID TAK -954-1009 Page 19of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Study Periods 2 and 3 a
Day
-1Day 1 Day 2 Day 3
Hours relative to start of infusion on Day 1 Hours relative to start of infusion on Day 2
Check -in Predose 0 1 1.083 1.25 3 9 Predose 0 0.5 1 2 4612 24 36
Pharmacodynamic Evaluations
Time to Onset of Defecation X------- --------- ---Continuous ------------- ------ X X  ---------------Continuous ------------- -X
Number of Stools per Day X------------- ------Continuous ------- ------------ X X  --------------- Continuous -------------- X
Stool Form (Bristol Stool Form Scale) X------------- ------Continuous ------ ------------- X X  --------------- Continuous -------------- X
Other
Confinement X----------------------------------- ---------------------- Continuous -------------- -------------- --------------------------------------- X
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK-954
Study ID TAK-954-1009 Page 20 of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Study Periods 2 and 3  aFollow-up (Day 16 
of Period 3 / 
10-14 days 
post last dose) / 
Early TermDay 8 Day 10 Day 12 Day 14 Day 16
Hours relative to start of infusion on Day 2
144 192 240 288 336
Administrative Procedures
Prior/Concomitant Medication Review X ---------- ------------------------ ------------- Continuous  ------------ --------------------- ------------X
Clinic Procedures/Assessments
Full Physical Examination X
Weight X
12-Lead ECG X X X X X
Orthostatic Vital Signs (HR, BP) X X X X X
Vital signs (HR, BP) X
Vital signs (RR, and T) X
Adverse Events Monitoring X----------------------------------- ------------- Continuous -- ------------ ---------------------------- --X
Pharmacokinetic Evaluations
Blood for Plasma TAK- 954  XXXXX
Other
Visit and return visits X X X X X
a. There will be a washout period of at least 16 days between the last dose in the previous period and the first dose of the nex t period.
b. Serum chemistry tests will be performed after at least an 8-hour fast; however, in case of dropouts or rechecks, participants  may not have fasted for 8 hours prior to the serum 
chemistry sample is taken.
c. To be performed at the end of infusion.
d. Urine will be collected at predose (spot sample) and from 0- 12, and 12-24 hours postdose on Da y 1 and from 0-12, 12-24, and 24 -36 hours on Day 2.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Usele ab
y 1414icaaa
on Day 2n Day 2pp
288288ap
thtththeheth-ContinuContinttto
ct tott oecbjessssusdanly
---------------oneuseee eeee
XXus
cial al
Xci
the last dohe last d
n 88--hour fahour
le) and froand fre
noCCI
TAK -954
Study ID TAK -954-1009 Page 21of 88
Protocol Incorporating Amendment No. 01 11 March 2019
4.0 INTRODUCTION
4.1 Background
TAK -954 i s a small  molecule 5-hydroxy tryptamine receptor 4 (5-HT4) agonist that exhibits 
prokinetic act ivity throughout the GI tract and is being developed for the treatment of disorders of 
reduced GI motilit y to accel erate GI recovery  post -surgery  (post -operative gastrointestinal 
dysfunct ion).
TAK -954 has been i nvest igated in healthy part icipants at single oral doses fro m 0.1 to 20 mg, 
multiple oral doses fro m 0.2 to 10 mg QD for 10 days, a single IV infusi on over 60 min of 0.2 mg 
in each of two periods in a crossover drug -drug interaction study and a single IV infusio n of 0.1 mg 
followed by mult iple doses of 0.5 mg for 3 days and mult iple IV doses of 0.5 mg QD for 5 days. 
After single and mult iple IV infusio n dosing in healt hy part icipants (0.2 m g and 0.1 single dose 
and 0.5 mg multiple doses over 1 hour), TAK -954 concentrations declined in a biphasic manner, 
with mean t 1/2value o f 22.6 hours, CL values of 7.17 L/h (119.5 mL/min) and Vz values o f 
230.37 L following single 0.2 mg dose. TAK -954 steady  state was achieved by  Day 3, wi th 
minimal accumulation o f TAK -
954 after m ultiple IV dosing of 0.5 mg. The increase in exposure 
from the 0.1 mg to 0.5 mg IV dose was approximately dose proportional, and the mean amount of 
TAK -954 excreted unchanged in urine on Day 5 ranged fro m 27.7% to 31.6%. A single IV dose of 
0.5mg TAK -954 has also been invest igated in crit ically ill pat ients with enteral  feeding 
intolerance and compared to metoclopramide. In patients who were crit ically ill and received 
0.5mg by IV infusio n, the exposure was slight ly less (C max5040 pg/m L and AUC 0
-2423,200 
pg·h/mL) compared to that observed in healt hy participants (C max6920 pg/mL and AUC 0-24 
41,500 pg·h/mL) fo llowing administration of a single 0.5 mg IV infusio n.
Clinical Safety
TAK -954 was generally well tolerated at doses of up to 10 mg (oral single dose) and mult iple 
doses of up to 5 mg (orally  for 10 day s) or doses of 0.5 mg (IV for 5 day s). No seri ous adverse 
events (SAEs) were reported across all Phase 1 studies. The most common AEs in part icipants 
receiving TAK -954 regardl ess of dose were headache, nausea, vo miting, di arrhea, and postural 
dizziness (IV dose only ) with no cl ear exposure response. No clinically  relevant trends in clinical 
laboratory  data, phy sical examinat ions, or ECGs (including QT interval data) were observed after 
single o r repeat oral or IV dosing. Although there were transient asymptomat ic increases in heart 
rate associ ated wi th TAK -954 administration all events resolved spontaneously , none were 
considered clinically significant by the invest igator, and a dose response wa s not evident. Adverse 
events associated with cardiovascular systems were dizziness, postural hypotensio n, and 
tachy cardi a. These were usually of short duration and resolved spontaneously. In the single 
ascending oral dose study , junctional rhyt hm was repo rted in 4 participants: 2 receiving 1 mg 
(isolated occurrences at 24 hours and 36 hours after dosing), and 2 receiving 20 mg (iso lated 
occurrence at 24 hours and in 1 of the 2, mult iple occurrences starting at 8 hours after dosing). 
ECGs were collected at the following time po ints: 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after 
dosing. There appeared to be a lack of an obvious dose related effect, the findings were far 
removed fro m time to maximum concentration (1-2 hours postdose), and in 3 o f the 4 partici pants 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 22of 88
Protocol Incorporating Amendment No. 01 11 March 2019
the finding was iso lated to a single ECG time point. Dose escalat ion in the study  was stopped at 
20mg, according to the protocol -specified stopping rules, because of the occurrence of two AEs o f 
moderate orthostatic hypotension. In the mult iple ascending oral dose study , no ECG findings of 
significance were reported in the first 3 cohorts (0.2 mg, 1 mg, and 5 mg, or placebo for 10 days). 
However, in Cohort 4 (10 mg), asymptomatic intermittent AV dissociat ion was reported in 2 of 
3participant s. The two participants had bradycardia approximately 50 bpm at baseline. One hour 
after receiving the first dose of TAK -954, both parti cipants developed intermittent AV 
dissoci ation. They  both received addit ional doses on study  day 2 bef ore being discont inued from 
the study .
Refer to the Invest igator’s Brochure (IB) for detailed background informat ionon TAK -954 [ 1].
4.2 Rationale for the Proposed Study
The IV formulat ion of TAK -954 was assessed at doses ranging from 0.1 to 0.5 mg with 0. 5 mg for 
5days being the m aximum  IV dose invest igated to date. TAK -954 was generally  well tol erated. 
This study  will further explore the safet y, tolerability , PD, and PK of IV doses of TAK -954 at 
higher dose levels to guide the select ion of a supratherap
eutic dose. This informat ion is needed in 
order to design a future study invest igating the potent ial of TAK -954 to prol ong the QTc interval.
4.3 Benefit/Risk Profile
The doses of TAK -954 administered in this study are not anticipated to induce any potential ri sk or 
benefit to participants participat ing in this study , as the predicted exposure levels are expected to 
be lower than the exposure levels found safe and well tolerated following oral dose administration 
of TAK -945 (see Section 6.3.2 ).
The safet y mo nitoring pract ices emplo yed by this protocol (ie, AE quest ioning, 12 -lead ECG, vital 
signs, orthostati c vital signs, clinical laboratory  tests, and phys ical examinat ions) are adequate to 
protect the participants’ safet y and should detect all expected TEAEs. In addit ion, a lead -in dose 
on Day 1 will be administered prior to receiving the full dose on Day 2 in order to reduce postural 
hypotension adverse ev ent. Based on the observation in a previous mult iple dose IV study  
(Theravance 0095), AE’s (moderate postural dizziness) seen on Day  1 after the 0.5 m g dose were 
not found when the Day  1 dose was reduced to 0.1 mg fo llowed by 0.5 m g doses on Days 2 
through 5.
There will be no direct healt h benefit for study participants from receipt of study drug. An indirect 
healt h benefit to the healt hy participants enro lled in this study is the free medical tests received at 
screening and during the study .
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK-954
Study ID TAK-954-1009 Page 23 of 88Protocol Incorporating Amendment No. 01 11 March 2019
5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Hypothesis
TAK-954 will be sufficiently safe and well-tolerated to permit continued clinical investigation.
5.2 Study Objectives5.2.1 Study Primar y Objectives
The primary objectives of the study are:
!To evaluate the safety and tolerability of single ascending IV doses of TAK-954.
!To evaluate the PK of single ascending IV doses of TAK-954.
5.2.2 Study Secondary Objective
The secondary objective of the study is:
!To evaluate the PD effect of single ascending IV doses of TAK-954 on the GI mo tility in 
healthy par ticipants while in confinement.
5.2.3 Study Explorator y Objectives
5.3 Endpoints
5.3.1 Primary Endpoints
The primary endpoints of the study are:
The following safety parameters of TAK-954 derived after a single dose of TAK-954 on Day 2 of 
each treatment period:
!TEAE assessments.
!Vital signs.
!12-lead ECG.
!Clinical laboratory testing (hematology, serum chemistry and urinalysis).
The following plasma PK parameters of TAK-954 derived after a single dose of TAK-954 on 
Day 2 of each treatment period:
!AUC
0-t: Area under the plasma concentration-time curve from time 0 to time of the last 
quantifiable concentration.Property of Takeda: For non-compointsoints
oints of tints of
safetsafet y yp
ment perint p
AE asseE ass
ViVitaltaliiii sill
!!12
!nly and subject to the applicable Terms of Useoon.n.
of TAK-of TA
doses of oses of
CCICCI
TAK-954
Study ID TAK-954-1009 Page 24 of 88Protocol Incorporating Amendment No. 01 11 March 2019
!AUC 0-inf: Area under the plasma concentration-time curve from time 0 to infinity, calculated 
using the observed value of the last quantifiable concentration.
!Ceoi: Observed plasma concentration at the end of infusion.
!CL: Total clearance after intravenous administration, calculated using the observed value of 
the last quantifiable concentration.
!Vz: Volume of distribution during the terminal disposition phase after intravenous 
administration, calculated using the observed value of the last quantifiable concentration.
The following urine PK parameters of TAK-954 derived after a single dose of TAK-954 on Day 2 
of each treatment period
!Ae: Amount of unchanged drug excreted in urine.
!fe: Fraction of IV dose excreted in the urine.
!CLR: Renal clearance.
5.3.2 Secondary Endpoints 
The secondary endpoint includes: 
The following PD parameters derived after a si ngle dose of TAK-954 on Day 2 of each treatment 
period
!Time to first stool.
!Number of stools per day.
!Stool form (Bristol Stool Form Scale).
5.3.3 Exploratory Endpoints
Propertommercial use only and subject to the applicable Terms of Usealue of ue of 
nous nous 
concentroncent
of TAKfT A K
single dongle do
Formorm Sc Smm
pointsoint
CCICCI
TAK-954
Study ID TAK-954-1009 Page 25 of 88Protocol Incorporating Amendment No. 01 11 March 2019
Property of Takeda: For non-commercial use only and subject to the ap UseCCICCI
TAK-954
Study ID TAK-954-1009 Page 26 of 88Protocol Incorporating Amendment No. 01 11 March 2019
6.0 STUDY DESIGN AND DESCRIPTION
6.1 Study Design
This is a double-blind, placebo-controlled, single ascending IV dose, 3-period, incomplete block 
design study to investigate the sa fety, tolerability and PK, and PD of TAK-954 at higher IV doses 
than those previously studied. In this Phase 1 study, healthy adult participants will attend a 
screening visit within 28 days prior to the first dose.
Participants will be randomized to one of 3 treatment sequences as detailed in the table below. In 
each sequence (see Section  9.1.1.1) , each participant w ill receive 2 doses of the active drug (out of 
3 evaluated dose levels) in an ascending order and 1 dose of placebo. A sample size of 
6 participants is proposed based on empirical considerations. 
On Day 1 of each period, each participant will receive a lead-in dose of 0.1 mg TAK-954 (if 
scheduled to receive a dose of active drug on Day 2 of that period as per the randomization 
schedule) or placebo (if scheduled to receive a placebo on Day 2 of that period as per the 
randomization schedule) as a 60-minute IV infusion. On Day 2 of each period, participants will 
receive either a single dose of 0.5 mg, 1 mg, or 2 mg TAK-954 or p lacebo as a 60-minute infusion 
as per the randomization schedule.
Safety will be assessed by monitoring for AEs, vital signs, orthostatic vital signs, ECGs, safety 
laboratory assessments, and physical examinations throughout each dosing period. Blood (for 
plasma) samples for assessment of TAK-954 c oncentrations will be collected at selected times 
from predose through to 9 hours after each lead-in dose (Day 1). Bl ood (for pl asma) samples for 
assessment of TAK-954 concentrations will also be collected at selected times from predose 
through 336 hours (Day 16) after each Day 2 dose. Urine samples for assessment of TAK-954 
concentrations will also be collected at selected times from predose through 36 hours (Day 3) after 
each Day 2 dose. . The 
time to first stool will be recorded following dosing on Day 1 until prior to dosing on Day 2 and 
following dosing on Day 2. The number of stools per day and stool form (Bristol Stool Form 
Scale) will be re corded following dosing on Day 1 until prior to dosing on Day 2, and for 36 hours 
following Day 2 dosing.
The last dose in the previous period and the first dose of the next period will be separated by a 
minimum of 16 days.
The starting dose of TAK-954 on Day 2 (Period 1) will be 0.5 mg, which is the highest dose 
previously used in a completed study following IV administration. Subsequent doses will be 
chosen based on emerging data; the currently proposed doses are 1 mg and 2 mg (see  Table 6.a) . 
Dose escalation to the next dose level (ie, next period) will not take place until the Investigator and 
the Sponsor have determined that adequate safety/tolerability from the previous period has been 
demonstrated to permit proceeding to the next dose level. Additional cohorts (approximately 6 
participants per cohort) may be enrolled if it is deemed appropriate by the Investigator and the 
Sponsor to rep eat a dose level or to study an interim dose level (lower than those planned) in a new 
cohort. For dose escalation and stopping rules see Section  6.2. Property of Takeda: For nnon-c ercial use only and subject to the applicable Terms of Useblock block 
IV doseV dos
end a end a 
the tablee tab
the active activ
ammple siple mmmm
ose of 0.se of 0
iod as peod as p
Dayay2 of2 ofyy tf
Dayay 2 of2 oyy
AKAK--95495
vital sigvital s
natioons thns 
954 conc54 co
each leadach lea
ons willns w
each Daeach D
lected ated a
recordee
Dayay 22yy. T
rded ded fofoll
dosingdosin
se in the e in the
m oof f 1616d
starting tarting
reviouslyevious
chosenchose
DosDo
thCCI
TAK -954
Study ID TAK -954-1009 Page 27of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Day 16 of Period 3 wi ll also be considered as the follow -up visit for participants who complete the 
study . All part icipants who received at least 1 dose of study drug or placebo and withdraw fro m the 
study  early  will return for a follow -up visi t, 10-14 days after the last dose administration.
Table 6.a Planned TAK -954 and Placebo Doses
Dose Infusion Duration
Lead -in 0.1 mg (100 mL x 0. 001mg/mL) 60 min
Treatment A 0.5 mg (100 mL x 0.005 mg/mL) 60 min
Treatment B (a) 1 mg (100 mL x 0.01 mg/mL) 60 min
Treatment C (a) 2 mg (100 mL x 0. 02mg/mL) 60 min
Placebo 100 mL 60 min
(a) The starting dose on Day 2 of Period 1 will be 0.5 mg, which is the highest dose previously used in a completed 
study following IV administration. Subsequent doses will be chosen based on emerging data; the currently proposed 
doses are 1 mg and 2 mg. D ose escalation to the next dose level (ie, next period) will not take place until the 
Investigator and the Sponsor have determined that adequate safety/tolerability from the previous period has been 
demonstrated to permit proceeding to the next dose level. Additional cohort(s) (approximately 6 participants per 
cohort) may be enrolled if it is deemed appropriate by the Investigator and the Sponsor to repeat a dose level or to 
study an interim dose level (lower than those planned) in a new cohort. For dose es calation see Section 6.2.
6.2 Dose Escalation
A decisio n to proceed to the next higher dose administration (next period) will be made by the 
Invest igato r and Sponsor representative(s) who will review all pertinent blinded safet y/tolerabilit y 
(eg, phy sical examinat ions, vital signs assessments, orthostatic vital signs, 12- lead ECGs, clinical 
laboratory  tests, and AEs) data through at least 10 days fo llowing Day  2 dosing in each period for 
at least 75% of participant s from the current period and those from all previous periods, as 
applicable .
Addit ional cohort (
s)(approximately 6 participants per cohort) may be enrolled if it is deemed 
appropriate by  the Inv estigator and the Sponsor to repeat a dose level or to study an interim dose 
level (lower than those planned) in a new cohort. 
When applicable, a written statement fully  docum enting the reasons for study terminat ion will  be 
provi ded to the Institutional R eview Board (IRB).
6.3 Rationale for Study Design, Dose, and Endpoints
6.3.1 Rationale of Study Design 
A rando mized, double -blind, pl acebo -controlled design has been selected to allow for unbiased 
analysis of safet y and tol erabili ty data foll owing single doses. A lead-in dose on Day 1 will be 
administered prior to receiving the treatm entdose on Day  2 in order to reduce postural 
hypotension adverse event. The starting treatm ent dose (Day  2) was selected to ensure the safet y of 
the participant s and is supported by  previous clinical  studi es. The different dose levels will be 
studi ed in a dose escalat ion study  design, in order to define doses that are anticipated to be safe. 
Dose escalat ion will be based on safet y and tol erabili ty from previ ous peri ods.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 28of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Parti cipants wil l be rando mized to treatment sequences to minimize assignment bias and a 
crossover design is used to reduce the residual variabilit y as every  parti cipant acts as their own 
control . However, an inco mplete block design where the 4 treatm ent (3 active and 1 p lacebo) will 
be randomized to 3 -period instead of 4 -period is proposed; all participant s will receive placebo 
treatm ent but will be rando mized to receive 2 out of 3 treatment dose (see Table 9.a). This will 
provi de the same informat ion as full design but in a shorter timeframe. As safet y and tolerabilit y is 
the primary  endpoint, the study  will be double -
blinded.
6.3.2 Rationale for Dose 
6.3.2.1 Starting Dose for This Study
The starting dose (Day 2) in Period 1 of this study is 0.5 mg IV, which is the maximum IV dose of 
TAK -954 reported from a completed study  to date. Ongoing clinical studi es (TAK -954- 2003) 
have administered 1 mg infusio n of TAK -954 over 60 min. Results for t hese studies are pending.
A lead-in dose of 0.1 mg will be administered on Day  1 for parti cipants randomized to receive 
TAK -954 on Day  2 to alleviate moderate postural dizziness as reported in previous studies.
6.3.2.2 Maximum Dose/Exposure for This Study
The m aximum tol erated oral  doses of TAK -954 were 10 mg single dose, and 5 mg QD mult iple 
doses for 10 days. Single oral doses of 20 mg were associated with moderate orthostatic 
hypotension (2 of 6 participants), and 2 of 3 participants with bradycardia at baseline discont inued 
multiple oral doses of 10 mg QD due to intermittent AVdissoci ation AEs that started 
approximately  one-hour post dosing on first day. Currently, the highest dose being invest igated for 
the inpatient use only is 0.5 mg administer ed IV QD for u
p to 10 day s (TAK -954- 2004). In 
addition, 1 m g is being investigated in Study  TAK -
954-2003.
Mean (standard deviat ion [SD]) TAK -954 exposure parameters (C maxand AUC), from oral and IV 
doses are presented in
 Table 6.b. Exposures predi cted f rom regressio n of IV data (Studies 
Theravance 0095 and TAK -954- 1004) are al so shown in  Table 6.b. Assuming dose proportional 
PK, the predicted C maxand AUC parameters for TAK -954 fo llowing the proposed maximum dose 
(2 mg IV) in this study are lower than those observed at oral doses associated with dos e-limiting 
arrhy thmia events.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 29of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Table 6.b Mean (SD) Actual and Predicted Exposure Parameters for TAK -954 after 
Oral and IV dosing
Route Study N Dose/RegimenCmax
(ng/mL) AUC (ng•h/mL)
Oral Theravance 0060 6 10mg single dose 94.4 (47.0) 1017 (327)a
6 20mg single dose 223 (60.0) 2462 (617)a
Theravance 0061 6 5 mg QD (Day 1) 19.0 (8.2) 211 (n=2)a
5 5mg QD (Day 10) 27.7 (5.2) 387 (830)b
3 10 mg QD (Day 1) 56.5 (20.3) 498 (n=1)a
1 10mg QD (Day 10) 64.6 796b
IV Theravance 0095 6 0.1mg (Day 1) 1.2 (0.3) 15.3 (n=1)
TAK -954-1004 0.2 mg single dose 2.64 (0.4) 28.6 (6.6)a
Theravance 0095 0.5mg (Day 1) 6.9 (2.1) 50.6 (5.4) c
Not applicable Predicted 2 mg single dose ~28 ~171a
Predicted 3mg single dose ~41 ~255 a
aAUC 0-inf.
bAUCtau.
cAUClast.
6.3.3 Rationale for Endpoints
6.3.3.1 Safety Endpoints 
The key safet y endpo ints are typical  for Phase 1 studies and will be assessed through monitoring o f 
adverse events, vital signs, orthostatic vital signs, ECGs, laboratory  assessments and physical 
examinat ions.
6.3.3.2 Pharmacokinetic Endpoints
The pharmacokinet ic endpo ints are standard for this ty pe of study .
6.3.3.3 Pharmacodynamic Endpoints 
Time to onset of defecat ion, number of stools per day, and stool consistency (form) are indicators 
of GI transi t.
6.3.4 Future Biomedical Research
Biomarker samples for DNA collected in this study may be used to understand how individu al 
genet ic var iation in participants impacts their study drug treatm ent response. This informat ion ma y 
also be used, for example, to develop a better understanding o f the safety and efficacy o f TAK-954 
and other studydrugs, to increase understanding of th e disease/condi tion being studied and other 
related condi tions, gain a better understanding of the drug pharmacology  and for generat ing 
inform ation needed for research, development, and regulatory approval of tests to predict response 
to TAK -954.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 30of 88
Protocol Incorporating Amendment No. 01 11 March 2019
6.3.5 Critical Procedures Based on Study Objectives: Timing of Procedures 
For thi s study , the primary  assessment i s safet y, tolerabilit y, and PK. The blood collect ion for 
plasma concentrations for TAK -954 are required to be collected as close to the scheduled t imes 
defined in this protocol as possible.
6.4 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
The starting dose of TAK -954 on Day  2 will be 0.5 mg. Subsequent doses will be chosen based on 
emerging data; the currently  proposed doses a re 1mg and 2 mg. Dose escalat ion to the next dose 
level (ie, next period) will not take place unt il the Investigator and the Sponsor have determined 
that adequate safet y/tolerabilit y from the previous peri od has been demonstrated to permit 
proceeding to t he next dose level. Addit ional cohorts (approximately  6 participants per cohort) 
may be enro lled if it is deemed appropriate by the Invest igator and the Sponsor to repeat a dose 
level or to study  an interim dose level (lower than those planned) in a new co hort. For addit ional 
details regarding dose escalat ion and stoppi ng rules see Section 6.2.
6.5 Study Beginning and End/Completion
6.5.1 Definition of Beginni ng of the Study
The beginning of the study will be defined as the beginning of screening (ie, signing of the ICF) of 
the first participant .
6.5.2 Definition of End of the Study
The end of study is defined as the date of the last scheduled study procedure (ie, Da y 16 of Period 3 
for parti cipants who com plete the study ) as outlined in the Schedule of Study  Procedures 
(Secti on3.0). For a participant who recei ved at least 1 dose of study drug or placebo and wit hdraw 
from the study early, the end o f study is de fined as the fo llow-up visit (ie, 10-14 days after the last 
dose administration).
6.5.3 Definition of Study Completion
The end o f the study is scheduled after c ompletion of the evaluat ions in Day 16 of Period 3 for the 
last participant in the study.
This t ime period may change in the event that the study is terminated early or the last participant is 
lost to foll ow-up, or if addit ional cohorts are enrolled to rep eat a dose level or to study an interim 
dose l evel.
6.5.4 Definition of Study Discontinuation
In consultat ion with the Sponsor, Celer ion reserves the right to terminate the study  in the interest 
of participant welfare.
The Sponsor reserves the right to suspend or terminate the study  at any  time.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 31of 88
Protocol Incorporating Amendment No. 01 11 March 2019
6.5.5 Criteria for Premature Termination or Suspension of the Study
The study  will be com pleted as pl anned unless one or more of the fo llowing cri teria are satisfied 
that require temporary  suspensi on or early  terminati on of  the study :
Study  stoppi ng rule for termination o f the study  (Secti on 6.2) is m et.
New informat ion or other evaluat ion regarding the safet y or efficacy of the study  medicat ion 
that indicates a change in the known risk/benefit profile for the product, such that the risk is no 
longer acceptable for participants participat ing in the study .
Significant vio lation of Good Clinical Practice (GCP) that compromis es the abilit y to achieve 
the primary  study  objectives or compromises participant safet y.
6.5.6 Criteria for Premature Termination or Suspension of a Site
NA
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 32of 88
Protocol Incorporating Amendment No. 01 11 March 2019
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF PARTICIPANTS
7.1 Inclusion Criteria 
1.Healthy, adul t, male or female, 18--55 y ears of age, inclusive, at screening.
2.Body  mass index (BMI) 
≥18 and ≤32.0 kg/m2, weighing ≥50 kg at screening.
3.Medically  healthy wi th no clinically  significant m edical history , physical examinat ion, 
laboratory  profi les, vital signs , orthostati c vital signs, or ECGs, as deemed by the Invest igator 
or desi gnee.
4.Continuous non -smoker who has not used nicoti ne-containing products for at least 3 months 
prior to the first dose and throughout the study , based on parti cipant self-reporting.
5.For a m ale or female o f childbearing potential, use an acceptable birth control method as 
indicated in Appendix D.
6.Understands the study  procedures in the ICF and be willing and able to comply wit h the 
protocol .
7.2 Exclusion Criteria
1.Is mentally  or legally incapacitated or has significant emotional problems at the time of the 
screening visit or expected during the conduct of the study .
2.History  orpresence o f clinically significant medical or psy chiatri c condi tion or di sease in the 
opinio n of the Invest igator or designee.
3.History  of any illness that, i n the opinio n of the Investigator or designee, might confound the 
resul ts of the study  or poses an additional risk to the parti cipant by  their parti cipat ion in the 
study .
4.History  or presence of alcoho lism or drug abuse within the past 2 years prior to the first dosing. 
5.History  or presence of hypersensit ivity or idiosyncrati c reacti on to the study  drug or rel ated 
compounds.
6.History  or presence of:
risk factors for Torsade de Pointes (eg, heart failure, unexplained syncope, 
cardi omyopathy , or f amily history  of Long QT Syndro me);
family history  of sudden death;
sick sinus syndrome, second or third degree AV block, myocardial infarct ion, pulmo nary 
congest ion, symptomat ic or significant cardiac arrhyt hmia, prolonged QTcF interval, or 
conduction abnormalit ies;
cholecystectomy;
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 33of 88
Protocol Incorporating Amendment No. 01 11 March 2019
orthostati c hypotensio n or orthostatic vital sign results at screening with a decre ase in 
systolic >20mmHg or decrease in diastolic >10mmHg, and increase in pulse o f >20bpm.
7.Female participants with a posit ive pregnancy test or who are lactating.
8.Positive urine drug or alcoho l resul ts at screening or first check -in.
9.Positive results a t screening for HIV, HBsA) or HCV.
10.Seated bl ood pressure is less than 100/60 mmHg or greater than 140/90 mmHg at screening.
11.QTcF interval is >450 msec (m ales and females) or has ECG findings deemed abnormal wit h 
clinical significance by  the Invest igator or designee at screening or first check -in including:
T wave forms which make accurate QT measurement difficult;
Absence of regular atrial or the presence of junct ional rhyt hm;
Abnorm al sinus rhy thm (heart rate <55 bpm or >100 bpm);
PR interval >210 msec, or QRS complex >110 msec.
12.Unable to refrain fro m or anti cipates the use of:
Any drug, including prescription and non -prescri ption medicati ons, herbal  remedies, or 
vitamin supplements beginning 14 days prior to the first dosing and throughout the study . 
After rando mizat ion, acetaminophen (up to 2 g per 24 hours) may be administered at the 
discreti on of the Investigator ordesignee. Acceptable birth control methods as described in 
Appendix Dwill be allowed
.
Any drugs known to be significant inducers of CYP3A4 enzymes and/or P -gp, including 
St. John’s Wort, for 28 days prior to the first dosing and throughout the study.
Serotonin antagonists, monoamine oxidase inhibit ors, sel ective serotonin reuptake 
inhibitors, serotonin and norepinephrine reuptake inhibitors, gamma -aminobut yric acid 
antagonists, and N -methyl-D- aspartate receptor antagonists for 14days prior to the first 
dosing and throughout the study .
Serotonin agonists for 28 days prior to the first dosing and throughout the study.
Appropriate sources (e g, Flockhart Table™)will be consulted to confirm lack of PK/PD 
interact ion with study  drug.
13. P articipant has infrequent bowel mo vements (less than approximately once per day ) within 
30days prior to fi rst dosing.
14.Recent history  of abnorm al bowel  movements, such as diarrhea, l oose stool s, or const ipation, 
within 2 weeks of first dosing.
15.Has been on a diet inco mpat ible with the onstudy -diet, in the opinio n of the Invest igator or 
designee, within the 30 days pri or to the first dosing and throughout the study .
16.Donati on of  blood o r significant blood loss within 56 days prior to the first dosing.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 34of 88
Protocol Incorporating Amendment No. 01 11 March 2019
17.Plasma donat ion within 7 days pri or to the first dosing.
18.Parti cipation in another clinical study  within 30 days prior to the first dosing. The 30 -day 
window will be derived fro m the date of the last blood collect ion or dosing, whichever is later, 
in the previous study  to Day 1 of Period1 of the current study .
7.3 Excluded Medications, Supplements, Dietary Products 
Concomitant medications will be prohibited as list ed in the exclusio n criteria in Sect ion 7.2. After 
the randomization, acetaminophen (up to 2 g per 24 hours) may be administered at the discret ion 
of the Investigator or designe e.Acceptable birth control methods as described in Appendix Dwill 
be allowed .
If deviat ions occur, the Investigator or designee in consultation wit h the Sponsor if needed will 
decide on a case by - -case basis whether the participant may  cont inue participa tion in the study .
All medications taken by participants during the course of the study  will be recorded.
Use of excluded agents (prescript ion or non -prescript ion) or dietary  products i s outlined in 
Table 7.a.
Table 7.a Excluded Medications, Supplements, and Dietary Products
CategoryBetween Screening and Randomization 
(Days -28 to predose [Day 1])Post-Randomization (Day 1) to 
Follow -Up 
Alcohol Prohibited from 48 hours prio r to first dosing Prohibited from 48 hours prio r to 
first dosing in each period and 
throughout the period of PK 
sample collection in each 
Treatment period.
Xanthine and/or caffeine Prohibited from 24 hours prio r to first dosing aProhibited from 24 hours prio r to 
first dosing in each period and 
throughout the period of PK 
sample collection in each 
Treatment period a.
Nicotine Prohibited from 3 month prior to first dosing Prohibited until end of PK 
collection in Treatment Period 3.
Medications See Sections 7.2and 7.3 See Sections 7.2and 7.3
Food substance
Grapefruit/Seville orange Prohibited from 14 days prior to first dosing Prohibited until end of PK 
collection in Treatment Period 3.
asmall amounts of caffeine derived from normal foodstuffs eg, 250 mL/8 oz./1 cup decaffeinated coffee or other 
decaffeinated beverage, per day, with the exception of espresso; 45 g/1.5 oz. chocolate bar, per day, would not be 
considered a deviation to this restriction.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 35of 88
Protocol Incorporating Amendment No. 01 11 March 2019
7.4 Diet, Fluid, Activity 
7.4.1 Diet and F luid
When confined to the CRU, water will be allowed ad libitum . Other fluids may be given as part of 
meals and snacks but will be restricted at all other times throughout the confinement period. 
Parti cipants will fast overnight for at least 8 hours prior to each dose and will remain fasted unt il at 
least 4 hours postdose.
When confined, standard meals and snacks will be provided at appropriate times, except when 
they are requi red to fast. When confined in the CRU, participants will be required to fast from all 
food and drink except water between meals and snacks.
Each m eal and/or snacks served at the CRU will be standardized and will be similar in caloric 
content and composit ion, and will be taken at approximately the same time in each period.
7.4.2 Activity
Participants will remain seated or semi -reclined for the duration of the infusion and for the first 
4hours postdose, except when they are supine or semi -reclined for study  procedures. Participants 
will then resume normal act ivity.
However, should AEs occur at any time, participants may be placed in an appropriate position or 
will be permitted to lie down.
Specific measures will be taken to prevent the participant fro m missing a urine collection and/or 
defecation by strictly controlling andprovi ding access to designated restrooms only . Partici pants 
will be asked to void prior to entering the shower.
Parti cipants will be instructed to refrain from strenuous phy sical activity which coul d cause 
muscle aches or injury, including contact sports at any t ime from screening unt il completionof the 
study .
7.5 Criteria for Discontinuation or Withdrawal of a Partici pant
Parti cipants are free to wi thdraw from  the study  at any time for any  reason. 
In addit ion, parti cipants m ay be withdrawn from  the study  by the invest igator or designee for the 
following reasons:
AEs;
Positive urine drug or alcoho l resul ts;
Positive pr egnancy  test;
Difficult ies in blood collect ion.
A part icipant may be wit hdrawn by the invest igator (or designee) or the Sponsor if enrollment into 
the study  is inappropriate, the study  plan is vi olated, or for administrative and/or other safet y 
reasons.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 36of 88
Protocol Incorporating Amendment No. 01 11 March 2019
7.6 Procedures for Discontinuation or Withdrawal of a Participant
The Investigator may  discontinue a participant’s study  parti cipat ion at any  time during the study  
when the participant meets the study  terminat ion criteria described in Sect ion 7.5. In addit ion, a 
participant m ay discont inue his or her participat ion without giving a reason at any time during the 
study . Shoul d a parti cipant’s parti cipat ion be discont inued, the primary criterio n for termination 
must be recorded by the investigator. In addit ion, efforts should be made to perform all procedures 
scheduled for the end- of-study  or early  terminat ion as described in Sect ion 3.0.
7.7 Participant Replacement
Discontinued parti cipants m ay be repl aced at the discretion of the Sponsor and the Invest igator.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 37of 88
Protocol Incorporating Amendment No. 01 11 March 2019
8.0 CLINICAL STUDY MATER IAL MANAGEMENT
8.1 Clinical Study Drug 
TAK -954 0.1 mg or placebo will be administered as a single IV lead -in dose on Day 1 followed by 
a single IV dose of TAK -954, or pl acebo on Day  2 of each study  period (as per randomizat ion 
sequence). See Table 6.aand  Table 9.afor detailed descript ion of treatments and treatment 
sequences, respectively.
The TAK -954 will be supplied in sealed cartons containing 1 single -use vial. The vial contains 
solution for infusio n. The drug product i s prepared in the CRU pharmacy  as an IV s olution. The 
solution will be prepared and labeled by licensed pharmacy staff according to the procedures 
outlined in the pharmacy manual. 
A saline so lution for IV infusio n will be used as placebo for the study . 
8.1.1 Clinical Study Drug Labeling
Study  drug co ntainers will be affixed with a clinical label in accordance wit h local regulatory  
requi rements.
8.1.2 Clinical Study Drug Inventory and Storage
The Sponsor will supply sufficient quant ities of TAK -954 to all ow com pletion of this study .
Celeri on will provide suf ficient quant ities of saline solutions to allow co mpletion o f the study. The 
same l ot number will be used throughout the study. 
The l ot numbers and expirat ion dates (where available) of the study  drugs supplied will be 
recorded in the final report.
Record s will be made of the receipt, preparation, dispensing, and final disposit ion of the study  
drugs supplied. All TAK
-954 products will be prepared and labeled by licensed pharmacy  staff  
according to the procedures outlined in the pharmacy  manual .
8.1.3 Clinical Study Drug Blinding
This is a double -blind, placebo con trolled study .
8.1.4 Randomization Code Creation and Storage 
A co mputerized rando mizat ion scheme will be created by  a Celeri on stati stician (who will not be 
involved in the analysis of the study data) and it shall be considered blinded (as per the fo llowing).
The randomization is available only to the CRU pharmacy staff that is preparing the drug who will 
not be invo lved in any other aspect of the study including administration o f the drug. It will not be 
made available to the Sponsor, participants, or members o f the staff responsible for the monitoring 
and evaluat ion of safet y assessments.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 38of 88
Protocol Incorporating Amendment No. 01 11 March 2019
In the absence of a medical emergency, the blinded randomizat ion for this study  will not be 
revealed unt il all data are en tered in the database, edits checks are performed, queries closed, case 
report forms (CRFs) signed by  the Invest igator, and the database is officially locked.
8.1.5 Clinical Study Blind Maintenance/Unblinding Procedure
One set of sealed envelopes containing the randomization code will be supplied to the Invest igator 
or desi gnee at the start of the study .
Breaking of the blind is expressly forbidden except in the event of a medical emergency where the 
ident ity of the drug m ust be known in order to properly  treat t he participant or in the event of an 
interim analysis. 
In the event of a medical emergency, it is requested that the Invest igator or designee make every 
effort to contact the Study Monitor or designee prior to breaking the blind. If breaking the blind is 
requi red because of a medical emergency , the treatment i denti ty woul d be revealed by  the 
Invest igator or designee, for that participant only. In the event that the emergency is one, in which 
it appears that the other participants may be at imminent risk, t he blind may be broken for all 
participants dosed at that dose level. The unblinding will be properly documente d in the study file .
In all cases where the code is broken, the Investigator or designee should record the date and 
reason for code breaking.
At the end of the study, envelopes will be retained or destroyed according to site procedures unless 
specified otherwise by  the Sponsor.
8.1.6 Accountability and Destruction of Sponsor- Supplied Drugs
Records will be made of the receipt and dispensing of the study d rugs supplied. At the conclusio n 
of the study, any unused TAK -954 study  drug will be retained by Celerio n, returned to the Sponsor 
or desi gnee, or destroyed, as per Sponsor instructions. If no supplies remain, this fact will be 
docum ented in the pharmacy  product accountabilit y records.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 39of 88
Protocol Incorporating Amendment No. 01 11 March 2019
9.0 STUDY PROCEDURES
9.1 Administrative Procedures
9.1.1 Informed Consent Procedure
The purpose of the study , the procedures to be carried out and the potential hazards will be 
described to the participants in non -technical terms. Particip ants will  be requi red to read, sign and 
date an ICF summarizing the discussio n prior to screening, and will be assured that they  may 
withdraw from  the study  at any  time wi thout jeopardi zing thei r medical  care.
Parti cipants will be given a copy  of their signed ICF.
9.1.1.1 Assignment of Screening and Randomization Numbers 
Each participant will be assigned a unique ident ification number upon screening. Participants who 
complete the study  screening assessments and meet all the eligibilit y criteria will be assigned a 
unique rando mization ident ification number at the time of the first dosing, different from the 
screening number, and will receive the corresponding product.
Parti cipants will be rando mized to 1 of 3 treatm ent sequences in a 1:1:1 ratio. The sequences to be
used in the rando mizat ion are detailed in Table 9.abelow. Participants will receive placebo and 2 
of the 3 TAK -954 doses.
Table 9.a Sequence Groups
SequencePeriod 1 Period 2 Period 3
Day 1
(Lead -in)Day 2
(Treatment)Day 1
(Lead -in)Day 2
(Treatment)Day 1
(Lead -in)Day 2
(Treatment)
Sequence 1 
(n=2)Placebo Placebo TAK -954 Treatment B TAK -954 Treatment C
Sequence 2 
(n=2)TAK -954 Treatment A Placebo Placebo TAK -954 Treatment C
Sequence 3 
(n=2)TAK -954 Treatment A TAK -954 Treatment B Placebo Placebo
If replacement participant s are used, the replaceme nt participant number will be 100 more than the 
original  (eg, Parti cipant No. 101 will replace Parti cipant No. 1).
9.1.1.2 Study Drug Assignment
This is a 3- period, inco mplete block design study . Parti cipants will receive placebo and 2 of the 
3TAK -954 doses as detailed in Section 6.1.
9.1.2 Inclusion and Exclusion 
Parti cipants will be screened in accordance with predefined inclusio n and exclusio n criteria as 
described in Sect ion 7.0.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 40of 88
Protocol Incorporating Amendment No. 01 11 March 2019
9.1.3 Medical History/ Demography
Medical history  and dem ographic data, including name, sex, age, race, ethnicit y, and history  of 
tobacco use will b e recorded.
9.1.4 Concomitant Medications
Concomitant medicat ions will be prohibited as listed in Section 7.2and in Sect ion 7.3. All 
medicat ions taken by  parti cipants during the course of the study  will be recorded.
9.2 Clinical Procedures and Assessments
The Schedule o f Study  Procedures (Secti on3.0) summarizes the clinical procedures to be 
perform ed at each visit. Individual clinical procedures are described in detail below. Addit ional 
evaluat ions/testing may be deemed necessary  by the invest igator or designee and/or the Sponsor 
for reasons rel ated to parti cipant safet y.
For thi s study , safet y, tolerabili ty and the collect ion of blood for plasma concentrations for 
TAK -954 i s a cri tical parameter and are required to be collected as close to the scheduled t imes 
defined in this protocol as possible. During infusio n, blood sam ples shoul d be collected from  the 
contral ateral arm opposi te the infusio n site. -All other procedur es should be co mpleted as close to 
the prescribed/scheduled time as possible, but can be performed prior or after the 
prescribed/scheduled time.
9.2.1 Physical Exam ination
Physical examinat ionswill be perform ed as outlined in the Schedule of Study  Procedures 
(Section3.0)
.
An abbreviated physical examination will include at the minimum, examinat ion of respiratory , 
cardi ovascular, and GI sy stems, wi th the option for further examinat ion of addit ional system s as 
necessary  based on reported symptoms/AEs.
Symptom -driven physical examinat ions may be performed at other times, if deemed necessary by 
the invest igator or designee.
9.2.2 Height and Weight
Body  height (cm) a nd weight (kg) willbe reported as outlined in the Schedule of Study Procedures 
(Secti on3.0).
9.2.3 BMI
BMI will be calculated based on the height and weight m easured at screening.
9.2.4 Vital Signs
Single measurements of body  temperature, respi ratory  rate, bl ood pressure and heart rate, 
orthostati c blood pressure and heart rate, will be measured as outlined in the Schedule of Study  
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 41of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Procedures (Section 3.0). Addi tional vital signs may  be taken at any  other times, if deemed 
necessary .
Blood pressure and heart rate measurements will be performed with partic ipants in a seated 
position, except when they  are supine or semi -reclined because of study  procedures and/or AEs 
(eg,nausea, dizziness) or if deemed necessary by the invest igator or designee.
For orth ostati c vital signs (heart rate and blood pressure), pa rticipants shoul d be seated and then 
stand upri ght pri or to m easurement of orthostatic vital signs, as per Celerio n standard operating 
procedures.
Vital signs will be measured prior to Day 1 dosing of each period for the predose time point. At all 
other pr edose time points vital signs will be measured within 2 hours prior to dosing. When 
scheduled postdose, vital signs will be performed within approximately 15 minutes of the 
scheduled time po int.
9.2.5 12-Lead ECG
Single 12 -lead ECGs will be performed as outlined in the Schedule of Study  Procedures 
(Secti on3.0)
. Addit ional ECGs may  be taken at any  other times, if deemed necessary  by the 
investigator or des ignee.
ECGs will be performed with part icipants in a supine posit ion. All ECG tracings will be reviewed 
by the investigator or designee.
ECGs will be measured prior to Day 1 dosing of each period for the predose time point. At all other 
predose time points vital signs will be measured wit hin 2 hours prior to dosing. When scheduled 
postdose, ECGs will be performed within approximately 20 minutes of the scheduled t ime point.
9.2.6 Study Drug Administration
TAK -954 IV sol ution will  be provi ded as described in Sect ion 8.1.
Lead -in dose and drug treatments are described in Table 6.a.
The IV dose will be administered over approximately 60 minutes. The start and end time of the IV 
infusio n will be recorded.
Hour 0 on Day  1 (Lead -in) will be defined as the start of IV infusion on Day 1. Hour 0 on Day  2 
(Treatm ent) will be defined as the start of IV infusion on Day  
2.
The pharmacy at the CRU will provide the IV dose ready  for the 60 minute infusio n in individual 
unit dose con tainers for each participant and for each study  period, as per the randomizat ion 
scheme 
(Table 9.a).
9.2.7 AE Monitoring
Parti cipants will be mo nitored throughout the study for adverse react ions to the study formulat ions 
and/or procedures as described in Sect ion 10.0.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 42of 88
Protocol Incorporating Amendment No. 01 11 March 2019
9.2.8 Laboratory Procedures and Assessments
All tests listed below will be performed as outlined in the Schedule of Study  Procedures 
(Secti on3.0). In addit ion, laboratory  safet y tests may  be performed at various unscheduled time 
points, if deemed necessary  by the investi gator or designee .
9.2.8.1 Clinical Laboratory Tests
Hematology
Hem atology will consist of the following tests:
Hemoglobin Red blood cell count
Hematocrit Platelet count
Total and differential leukocyte count
Chemistry 
Serum  chemistry  tests will be performed after at least an 8-hour fast; however, in case o f dropouts 
or rechecks, participants may  not have fasted for 8 hours prior to the serum chemistry  sample is 
taken.
Chemistry  evaluat ions will consist of the fo llowing standard chemistry  panel
Blood Urea Nitrogen Sodium
Bilirubin (total and direct) Potassium
Alkaline phosphatase Chloride
Aspartate aminotransferase Glucose 
Alanine aminotransferase (ALT) Creatinine *
Albumin
* At screening, creatinine clearance will be calculated using the Cockcroft Gault formula.
Urinalysis
Urinalysis will consist of the fo llowing tests:
pH Bilirubin
Specific gravity Blood *
Protein * Nitrite *
Glucose Urobilinogen
Ketones Leukocyte esterase *
* If urinalysis is positive for protein, blood, nitrite and/or leukocyte esterase, amicroscopic examination (for red blood 
cells, white blood cells, bacteria, casts, and epit helial cells) will be performed.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK-954
Study ID TAK-954-1009 Page 43 of 88Protocol Incorporating Amendment No. 01 11 March 2019
Other 
HIV test Urine drug screen
– Opiates (includes morphine, heroin 
(diacetylmorphine), codeine, 6-acetylmorphine, dihydrocodeine, hydrocodone, thebaine, and, 
hydromorphone)
– Amphetamines
– Barbiturates
– Benzodiazepines
– Cocaine
–CannabinoidsHBsAg
HCV
Urine alcohol screen
Serum pregnancy test (human chorionic gonadotropin 
[hCG])
9.3 PK, PD, and Biomarkers Samples
Primary specimen collection par ameters are provided in Table 9.b.  Instructions for plasma, blood 
and urine samples processing and handling will be provided in a separate document(s).
Table 9.b Primary Specimen Collections
Specimen NamePrimary 
SpecimenPrimary 
Specimen 
Derivative Description of Intended UseSample 
Collection
Plasma sample for TAK -954 PK Blood Plasma Plasma sample for PK analysis Mandatory
Blood for DNA analysis Blood DNA Biomarker analysis Optional
Urine sample for TAK -954  Urine Urine Urine sample for PK analysis Mandatory
9.3.1 PK Measurements 
All plasma and urine samples from all participants  receiving active drug will be analyzed. Only the 
Day 2 predose and end of infusion (1 hour postdose) plasma samples will be analyzed from 
participants when receiving placebo treatment. No urine sample from participants receiving 
placebo will be analyzed.
The PK parameters of TAK-954 will be derived using non-compartmental analysis methods and 
will be determined from the concentration-time data for all evaluable participants. Actual 
sampling times, rather than scheduled sampling times, will be used in all PK computations 
involving sampling times. A more detailed description will be given in the clinical pharmacology 
analysis plan (CPAP).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Userphine, rphine, 
ne, and, , and, 
th
able le 9.b9.b
vided in aded in
rimary mary
Specimepecim
DerivaDerly
Puuus
Bloododcia
UrUrineiner
ooom
ments ents 
rine samne sam
e and end and e
s when rewhe
willwill b blle ae
PK paraPK pa
ill be deill be d
samplisamp
invoinv
aCCI
CC
I
TAK-954
Study ID TAK-954-1009 Page 44 of 88Protocol Incorporating Amendment No. 01 11 March 2019
9.3.1.1 Plasma for PK Measurements
No PK parameters will be calculated for participants with detectable at 2 or fewer consecutive time 
points. 
Individual and mean plasma concentration-time curves (both linear and log-linear) will be 
included in the final report.
Other PK parameters may be calculated, if deemed necessary, for the interpretation of the data. All 
efforts will be made to obtain the PK samples  at the exact nominal time relative to dosing. 
However, samples obtained within the time windows indicated in  Table 9.c will not be captured as 
a protocol deviation, as long as the exact time of dosing and the sample collection is noted on CRF.
Table 9.c Pharmacokinetics Sample Collection Time Window
Time window (minutes) Nominal Sample Time
Up to 30 minutes prior to dose Predose
±2 Immediately post start of infusion to 1.25 hours
±5 >1.25 hours to 6 hours
±10 >6 hours to 36 hours
±30 >36 hours
Property of T±30±30f Takeda: For non-commercial use onlyants wints w
on-time ctime
ulated, ifated, 
he PK sae PK 
within thwithin 
ong as thng as t
mamacokico
indow (mindowrn
utes priores prFoa: ed
00ak
fTof Use CCICCI
TAK-954
Study ID TAK-954-1009 Page 45 of 88Protocol Incorporating Amendment No. 01 11 March 2019
9.3.1.2 Urine for PK Measurements
9.3.2 PD Measurements 
The time to first stool and number of stools per day will be recorded. Stool samples will be 
collected and stool form (Bristol Stool Form Scale) will be assessed by the appropriate qualified 
clinic staff. Stool samples will not be stored and will be discarded following the recording of PD 
evaluations.
The following parameters derived following dos ing on Day 1 until prior to Day 2 dosing and 
following dosing on Day 2 of each treatment period will be assessed:
!Time to first stool.
!Number of stools per day.
!Stool form (Bristol Stool Form Scale).
9.3.3 Biomark ers Measurements 
Blood samples for DNA will be collected to identi fy biomarkers that are predictive of efficacy, 
resistance to and or safety of treatment with TAK-954 and for genotyping variations in genes 
encoding drug metabolizing enzymes (DME) or drug transporters that might be implicated in 
TAK-954 disposition.
All biomarkers samples collected will be stored by the Sponsor or bioanalytical facility for 
15 years following the last dosing. Tubes will be  identified with a barcode using an appropriate 
label. Samples will not be submitted to a public database. The sponsor and contract research 
organizations involved in the clinical conduct,  bioanalytical analyses and PK and statist ical 
analyses of the data will have access to the samples and /or the data that resulted from the analysis, 
if performed. By signing the ICF, participants agree to the possible future analysis of these 
samples. At any time, the participants can contact the clinical research unit (CRU) staff to 
requested destruction of the samples. Any addition al research on these samples unspecified by this 
protocol will require approval from the participants.
Property of Takeda: For non-commercial use only and subject to thded. Stooed. St
sessed byessed 
carded farded 
on Dayn Day
od will bwill
cale)cale) .
ments ents 
ll be col be co
y y ofof tre trff
olizizing eing
on.n.
s samples sam
lowing wing
amples wmples 
nizatatioionsn
alyses oalyses o f
if perforf perfo
sampsam
req of UseCCI CCI
TAK -954
Study ID TAK -954-1009 Page 46of 88
Protocol Incorporating Amendment No. 01 11 March 2019
9.3.4 Confinement
In each treatment period, participant s will be housed on Day  -1, at the time indicated by  the CRU
until after the 36 -hour blood draw and/or study  procedures on Day  3. Participant s will return for 
study  procedures as indicated in the Schedule of Study  Procedures (Secti on3.0).
At all times, a participant may be required to remain at the CRU for longer at the discretion of the 
Invest igator or designee.
As per si te preference, participant s may be confined throughout the washout period(s). If the 
washout period is exact ly 14 days, Days 15 and 16 of Period 1 and/or Period 2 may occur on 
Days -1 and 1 of Period 2 and/or Period 3, respectively.
Day 16 of Period 3 will also be considered as the follow -up visit for participants who complete the 
study . All part icipants who received at least 1 dose of study drug or placebo and withdraw fro m the 
study  early  will return for a follow -up visi t, 10-14 days after the last dose administration.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 47of 88
Protocol Incorporating Amendment No. 01 11 March 2019
10.0 ADVERSE EVENTS
10.1 Definitions and Elements of AEs
An AE is defined as any untowar d medical occurrence in a clinical invest igation participant who 
has signed informed consent to participate in a study; it does not necessarily have to have a causal 
relationship with the treatment.
An AE can therefore be any unfavorable and unintended sig n (eg, a clinically significant abnormal 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a drug, whether or 
not it is considered related to the drug.
An untoward finding generally may:
Indicate a new diagnosis or unexpected w orsening of a preexist ing condit ion. (Intermittent 
events for pre -exist ing condit ions or underlying disease should not be considered AEs.)
Necessitate therapeutic intervent ion.
Requi re an invasive diagnostic procedure.
Requi re discontinuation or a change i n dose of study medicat ion or a concomitant medicat ion.
Be considered unfavorable by the invest igator for any reason.
Diagnoses versus signsand symptoms:
Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (including 
abnorm allaboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory  values or ECG parameters maybe considered AEs if they are judged to 
be clinically  significant (i e, if som e act ion or intervent ion is required or if the investigator 
judges the change to be beyo nd the range of normal physio logic fluctuati on). A l aboratory  
re-test and/or continued monitoring of an abnormal value are not considered an intervention. In 
addition, repeated or addit ional noninvasive testing for verificat ion, evaluat ion or m onitoring 
of an abnorm ality is not considered an intervention.
If abnormal laboratory va lues or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal failure), the diagnosis only should be 
reported appropriately  as an AE.
Pre-exist ing condit ions:
A pre -exist ing condit ion (present at the time of signing of informed consent) is considered a 
concurrent medical history  condi tion and shoul d NOT be recorded as an AE. A baseline 
evaluat ion (eg, laboratory  test, ECG, X -ray, etc) shoul d NOT be recorded as an AE unless 
related to a study  proc edure. However, if the participant experiences a worsening or 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 48of 88
Protocol Incorporating Amendment No. 01 11 March 2019
complicat ion of such a concurrent medical history  condi tion, the worsening or complication 
shoul d be recorded appropriately as an AE (worsening or complicat ion occurs after informed 
consent is s igned). Investigators should ensure that the event term recorded captures the 
change in the condit ion (eg, “worsening of…”).
If a participant has a pre -exist ing episodic condit ion (eg, asthma, epilepsy ), any occurrence of 
an episode should only be captured as an AE if the episodes beco me more frequent, serious, or 
severe in nature, that is, invest igators should ensure that the AE term recorded captures the 
change from Baseline in the condit ion (eg “worsening of…”).
If a participant has a degenerat ive concur rent condit ion (eg, cataracts, rheumatoid arthrit is), 
worsening of the condit ion should only be captured as an AE if occurring to a greater extent to 
that which would be expected . Again, investigators should ensure that the AE term recorded 
captures the ch ange in the condit ion (eg, “worsening of…”).
Worsening of AEs:
Ifthe parti cipant experiences a worsening or complicat ion of an AE after the first 
administration of study  medicati on or after any  change in study  medicat ion, the worsening or 
complicat ion sho uld be recorded as a new AE. Investigators should ensure that the AE term 
recorded captures the change in the condit ion (eg, “worsening o f…”).
Changes in severit y of AEs:
If the participant experiences a change in the severit y of an AE that i s not associated with a 
change in study  medicati on, the event shoul d be captured once with the maximum severit y 
recorded.
Prepl anned surgeries or procedures:
Prepl anned procedures (surgeries or therapies) that were scheduled prior to signing of 
inform ed consent are not considered AEs. However, if a preplanned procedure is performed 
early (eg, as an emergency) due to a worsening of the pre -exist ing condit ion, the worsening of 
the condi tion shoul d be captured appropriately  as an AE. Com plicati ons resul ting fro m any 
planned surgery  should be reported as AEs.
Elect ive surgeries or procedures:
Elect ive procedures performed where thereis no change in the participant’ s medical condit ion 
shoul d not be recorded as AEs but should be documented in the participant’s source 
docum ents. Com plicat ions result ing from an elect ive surgery should be reported as AEs.
Overdose:
An overdose is defined as a known deliberate or accident al administrati on of  investigational 
drug, to or by  a study parti cipant, at a dose above that which is assigned to that individual 
participant according to the study  protocol . It is up to the invest igator or the reporting 
physician to decide whether a dose is to be considered an overdose, in consultat ion with the 
Sponsor.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 49of 88
Protocol Incorporating Amendment No. 01 11 March 2019
All cases of overdose (with or without associated AEs) will be documented on an Overdose 
page of the CRF, in order to capture this important safet y information consistent ly in the 
database . AEs associ ated wi th an overdose will be documented on AE CRF(s) according to 
Secti on 10.0.
Serious adverse events ( SAEs ) of overdose should be re ported according to the procedure 
outlined in Sect ion 10.2.8 .
In the event of drug overdose, theparticipant should be treated symptomat ically.
10.1.1 SAEs
An SAE is defined as any untoward medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENING.
The term “life threatening” refers to an event in which the participant was at risk of death at 
the time ofthe event; it does not refer to an ev ent that hypothetically  might have caused 
death if it were more severe.
3.Requi res inpat ient HOSPITALIZATION or prolongation of exist ing hospitalizat ion.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDICAL EVENT that satisfies any of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the parti cipant to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospita lizati on.
Includes any event or synonym described in the Takeda Medically  Significant AE List 
(Table 10.a).
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 50of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Table 10.a Takeda Medically Significant AE List 
Term
Acute respiratory failure/acute respiratory 
distress syndromeHepatic necrosis
Acute liver failure
Torsade de pointes / ventricular fibrillation / 
ventricular tachycardiaAnaphy lactic shock
Acute renal failure
Malignant hypertension Pulmonary hypertension
Convulsive seizures Pulmonary fibrosis
Agranulocytosis Confirmed or suspected endotoxin shock
Aplastic anemia Confirmed or suspected transmission of infectious agent by 
a medicinal productToxic epidermal necrolysis/
Stevens -Johnson syndrome Neuroleptic malignant syndrome / malignant hyperthermia
Spontaneous abortion / stillbirth and fetal death
AEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
reported and followed up in the same manner (see Sections 10.1 and 10.1.1 ).
10.1.2 Special Interest AEs
NA
10.2 AE Procedures
10.2.1 Assigning Severity/Intensity of AEs
The different categories o f severit y/intensity are:
Mild: An adverse event that is usually transient and may require only  minimal 
treatm ent or therapeutic intervent ion. The event does not generally interfere 
with usual  activi ties of  daily living.
Moderate: An adverse event that is usually alleviated w ith addit ional specific therapeut ic 
intervent ion. The event interferes wit h usual activit ies of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research 
participant.
Severe: An adverse event that interrupts usual activit ies of daily living, or significant ly 
affects clinical status, or may require intensive therapeutic intervention.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 51of 88
Protocol Incorporating Amendment No. 01 11 March 2019
10.2.2 Assigning Causality of AEs
The rel ationship of each AE to study  medicati on(s) will be assessed using the fo llowing 
categori es:
Relate d: An AE that fo llows a reasonable temporal sequence fro m administration of a 
drug (including the course after withdrawal o f the drug), or for which a causal 
relationship is at least a reasonable possibilit y, ie, the relati onship cannot be 
ruled out, although factors other than the drug, such as underlying diseases, 
complicat ions, conco mitant drugs and concurrent treatments, may also be 
responsible.
Not Rel ated: An AE that does not follow a reasonable temporal sequence fro m ad ministration 
of a drug an d/or that can reasonably be explained by other factors, such as 
underlying diseases, complicat ions, conco mitant medi cations and concurrent 
treatm ents.
10.2.3 Start Date 
The start date of the AEis the date that the first signs/symptoms were noted by  the parti cipant 
and/or invest igator.
10.2.4 End Date 
The end date of the AE is the date at which the participant recovered, the event resolved but with 
sequelae or the participant died.
10.2.5 Pattern of Adverse Event (Frequency) 
Episodi c AEs (eg, headache) or those which occur repeatedly over a period of consecutive days are 
intermittent. All other events are continuous.
10.2.6 Action Taken With Study Treatment
Drug withdrawn –a study  medicat ion is stopped due to the particular AE.
Dose not changed –the particular AE did not require stopping a study  medicat ion.
Unknown –only to be used if it has not been possible to determine what action has been taken.
Not applicable –a study  medicat ion was stopped for a reason other than the particular AE 
eg,the study  has been terminated, the par ticipant died, dosing wit h study  medicat ion had not 
yet started or dosing with study  medicat ion was already  stopped before the onset of the AE.
Dose reduced –the dose was reduced due to the particular AE.
Dose increased –the dose was increased due to the particular AE.
Drug interrupted –the dose was interrupted due to the particular AE.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 52of 88
Protocol Incorporating Amendment No. 01 11 March 2019
10.2.7 Outcome 
Recovered/reso lved –participant returned to first assessment status with respect to the AE.
Recovering/resolving –the intensit y is lowered by  one or m ore stages: the diagnosis has or 
signs/symptom s have alm ost disappeared; the abnormal laboratory  value improved, but has 
not returned to the normal range or to the baseline value; the participant died from a cause 
other than the particular AE with the condit ion remaining “recovering/reso lving.”
Not recovered/not resolved –there is no change in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, signs/symptoms or laboratory  value on the l ast day  of the observed 
study peri od has beco me worse than w hen it started; is an irreversible congenital ano maly; the 
participant di ed fro m another cause with the part icular AE state remaining “Not recovered/not 
resolved.”
Recovered/ Reso lved wit h sequelae –the participant recovered from an acute AE but was left 
with perm anent/si gnificant impairment (eg, recovered fro m a cardiovascular accident but with 
some persisting paresis).
Fatal  –an AE that is considered as the cause of death.
Unknown –the course of the AE cannot be fo llowed up due to hospi tal change or re sidence 
change at the end of the participant’s part icipation in the study .
10.2.8 Collection and Reporting of AEs, SAEs, Special Interest AEs, and Abnormal LFTs
10.2.8.1 Collection Period
Collect ion of AEs ( ie, AEs, SAEs, Special Interest AEs, and Abnormal liver funct ion tests [LFTs])
will co mmence at the time the participant signs the informed consent. Routine co llection of AEs 
will cont inue unt il the fo llow-up visit on Day 16 of Period 3 or 10 -14 days fo llowing the last study 
drug administration for participants who with draw fro m the study  early . For parti cipants who 
discontinue prior to the administration of study  medication, AEs will be fo llowed unt il the 
participant discont inues study participat ion. 
10.2.8.2 Reporting AEs
At each study  visit, the investi gator will assess wheth er any  subjective AEs have occurred. A 
neutral  quest ion, such as “How have you been feeling since your last visit ?” may be asked. 
Parti cipants may  report AEs occurring at any  other time during the study . Parti cipants 
experiencing an SAE prior to the first exposure to investigational product must be monitored until 
the symptom s subsi de and any  clinically relevant changes in laboratory  values have returned to 
Baseline or there is a satisfactory  explanat ion for the change. Non -serious AEs that begin prior to 
the first exposure to invest igational product, related or unrelated to the study  procedure, need not 
be followed-up for the purposes of the protocol.
All participants experiencing AEs, whether considered associated with the use of the study  
medicat ion or no t, must be m onitored until  the symptom s subsi de and any  clinically relevant
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 53of 88
Protocol Incorporating Amendment No. 01 11 March 2019
changes in laboratory  values have returned to Baseline or un til there is a satisfactory  explanat ion 
for the changes observed. All AEs will be documented in the AE page of the CRF, whether or not 
the invest igator concludes that the event is related to the drug treatment. The fo llowing 
inform ation will be documented for each event:
Event term;
Start and end date and time;
Pattern of AE (frequency);
Severit y/Intensi ty;
Causalit y (Inves tigator’s opinio n of the causal relationship between the event and 
administration of study  drug[s]);
Action taken with study  drug;
Outcom e of event;
Seriousness.
10.2.8.3 Reporting SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
procedure outlined below:
A Takeda SAE form must be co mpleted, in English and signed by the invest igator immediately or 
within 24 hours of first onset or notification of the event. The informat ion should be co mpleted as 
fully as possible b ut contain, at a minimum:
A short descript ion of the event and the reason why  the event i s categori zed as serious ;
Parti cipant i dentificat ion number;
Invest igator’s name;
Nam e of the study  medicat ion(s);
Causalit y assessment.
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Secti on 14.1.1 .
Any SAE spontaneously reported to the invest igator fo llowing the AE collect ion period should be 
reported to the Sponsor if considered related to study  parti cipat ion.
Reporting of SAEs that begin before first administration of investigational product will fo llow the 
same procedure for SAEs occu rring on treatment.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 54of 88
Protocol Incorporating Amendment No. 01 11 March 2019
SAE Follow -Up
If informat ion is not available at the time o f the first report becomes available at a later date, the 
investigator should complete a fo llow-up SAE form  or provi de other writtendocum entati on and 
fax it immediately wit hin 24 hours of receipt. Copies of any relevant data from the hospital notes 
(eg, ECGs, laboratory  tests, di scharge summary, postmortem results) should be sent to the 
addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
10.2.8.4 Reporting Special Interest AEs 
NA
10.2.8.5 Reporting of Abnormal LFTs
If a participant is noted to have ALT or AST elevated >3 × upper limit of normal ( ULN) on 
2consecutive occasio ns, the abnormalit y shoul d be recorded as an AE. In addition, an LFT 
Increases CRF must be completed providing addit ional  informat ion on relevant recent history, risk 
factors, clinical signs and symptoms and results of any addit ional diagnostic tests performed.
If a participant is noted to have ALT or AST >3 ×ULN and total bilirubin >2 ×ULN for which an 
alternat ive etio logy has not been i dentified, the event should be recorded as an SAE and reported 
as per Secti on 10.2.8.3 . The i nvest igator must contact the Medical Monitor for discussio n of the 
relevant parti cipant details and possible alternat ive etiologies, such as acute viral hepati tis A or B 
or other acute liver disease. Follow -up laboratory  tests as described in Sect ion 9.2.8 must also be 
perform ed. In addit ion, an LFT Increases CRF must be completed and transmitted with the Takeda 
SAE form (as per Section 10.2.9 )
. 
10.2.9 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities 
The Sponsor will be responsible for reporting all suspected unexpected serious adverse react ions 
(SUSARs) and any other applicable SAEs to regulatory  authori ties, invest igators and IRBs or 
IECs, as applicable, in accordan ce wi th national regulat ions in the countries where the study  is 
conducted. Relat ive to the first awareness of the event by/or further provisio n to the Sponsor or 
Sponsor’s designee, SUSARs will be submitted within 7 days for fatal and life -threatening eve nts 
and 15 days for other serious events, unless otherwise required by nat ional regulat ions. The 
Sponsor will also prepare an expedited report for other safety issues where these might materially 
alter the current benefit -risk assessment of an investigat ional medicinal product or that would be 
sufficient to consider changes in the investigat ional medicinal products administration or in the 
overall conduct of the study . The invest igational site al so will forward a copy  of all expedited 
reports to his or her IRB or IEC in accordance wit h national regulat ions.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 55of 88
Protocol Incorporating Amendment No. 01 11 March 2019
11.0 STATISTICAL METHODS
11.1 Statistical and Analytical Plans
All statistical analysis o f the study  will be performed using the statist ical software, SAS 
versio n9.3 or hi gher Details concerning the standards for precisio n, decimals, descriptive 
statist ics will be in the Statistical Analysis Plan (SAP).
Detailed methodology  for summary  and stati stical analyses o f the data collected in this study  will 
be docum ented in a SAP. This docum ent will provide further detail s regarding the definit ion of 
analysis variables and analysis methodology  to address all study  object ives. Addi tional stati stical 
analyses other than those described in this section may be performed if deemed appropriate.
11.1.1 Analysis Sets
11.1.1.1 Safety Set
All participants who received at least one dose of the study  drug (acti ve or pl acebo) will  be 
included in the safet y evaluat ions.
11.1.1.2 PK Set
Samples fro m all parti cipants will be assayed even if the participants do not complete the study . 
All part icipants who comp ly sufficient ly with the protocol and display an evaluable PK profile (eg, 
exposure to treatm ent, availabilit y of measurements and absence o f major protocol vio lations) will 
be included in the statist ical analyses.
11.1.1.3 PD Set
All participants who received at l east one dose of the study  drug (acti ve or pl acebo) and have at 
completed at l east 1 PD sam pling peri od and/or have at least 1 evaluable parameter will be 
included in the PD evaluat ions.
11.1.2 Analysis of Demography and Other Baseline Characteristics
Continuous demographic data (i e, age, wei ght, height, and BMI) will be listed and summarized 
using appropriate summary statist ics. Categori cal dem ographic data (i e, gender, race, and 
ethnicit y) will also be listed and tabulated.
11.1.3 Safety Analysis
All safet y data will b e popul ated in the individual CRFs and listed by  parti cipant.
Dosing dates and t imes (including beginning and end of infusion) will be listed by part icipant.
Quant itative safet y data as well as the difference to baseline, when appropriate, will be 
summariz ed using the appropri ate descri ptive stati stics.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK-954
Study ID TAK-954-1009 Page 56 of 88Protocol Incorporating Amendment No. 01 11 March 2019
11.1.3.1 AEs
AEs will be coded using the most current versi on of Medical Dictionary for Regulatory Activities 
(MedDRA®) available at Celerion and summarized by treatment for the number of participants 
reporting the TEAE and the number of TEAEs reported. A by-participant AE data listing including 
verbatim term, coded term, treatment, severity, and relationship to treatment will be provided.
11.1.3.2 Clinical Laboratory Evaluation
Clinical laboratory results will be summarized  by treatment and point of time of co llection and a 
shift table describing out of normal range shifts will be provided.
11.1.3.3 Vital Signs
Vital signs assessments will be summarized by treatment a nd point of time of collection.
11.1.3.4 ECGs
ECGs will be summarized by treatment and point of time of co llection.
11.1.3.5 Other Safety Parameters
Physical examination findings will be presented in the data listings.
Medical history, and concurrent conditions will be coded using the MedDRA®and concomitant 
medications will be coded using the World Healt h Organization (WHO) drug dictionary and will 
be listed by participant.
11.1.4 PK Analysis
Descriptive statistics will be provided for the TAK-954  concentrations, as 
applicable, and PK parameters (plasma and urine) using appropriate summary statistics to be fully 
specified in the CPAP.
PK parameters for plasma concentrations will be calculated as described in Section  9.3.1.1 and for 
urine, as described in Section  9.3.1.2,  respectively.
Dose proportion ality will be  assessed graphically.
11.1.5 PD Analysis
Descriptive statistics will be provided for time to first stool and number of stools per day using 
appropriate summary statistics to be  fully specified in the SAP.
Stool form (using Bristol Stool Form Scale [Lewis SJ, Heaton KW. Stool form scale as a useful 
guide to intestinal transit time. Scand J Gastroenterol. 1997 Sep;32(9):920-4. Lewis and Heaton 
1997] ) will be listed.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Uses 
s 
cluding luding 
vided.ided.
of cocollectlle
t of timeof tim
e of coe of co llel
d in the din the
will be will be
rld Healtd Hea
e provideprovid
meters (peters (
r plasma plasm
bed in Sed in 
ortitionaliton
PD AnPD A
Descriptescript iv
appropappro
StoCCI
TAK -954
Study ID TAK -954-1009 Page 57of 88
Protocol Incorporating Amendment No. 01 11 March 2019
11.2 Interim Analysis and Criteria for Early Termination
A blinded safety  and tolerabilit y assessment will be conducted by  the Invest igator and sponsor 
representative(s) prior to proceeding to the next higher dose level (next period) according to the 
dose escalat ion and stoppi ng ru les outlined in Sect ion 6.2.
11.3 Determination of Sample Size
The sample size of 6 healthy male and female participants is empirical, was selected with out 
statist ical considerat ions, and is deemed adequate to meet the study object ives. Addit ional cohorts 
(approximately 6 participants per cohort) may be enro lled if it is deemed appropriate by the 
Invest igator and the Sponsor to repeat a dose level or to s tudy an interim  dose l evel (l ower than 
those pl anned) in a new cohort.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 58of 88
Protocol Incorporating Amendment No. 01 11 March 2019
12.0 QUALITY CONTROL AND QUALITY ASSURANC E
12.1 Study -Site Monitoring Visits
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the proto col are followed. Source documents will be reviewed for verificat ion of data 
recorded on the CRFs. Source documents are defined as original documents, data, and records. 
The invest igator and study site guarantee access to source documents by the Sponsor or its 
designee (CRO) and by  the IRB or IEC.
All aspects of the study  and i ts docum entati on will be parti cipant to review by the Sponsor or the 
Sponsor’s designee (as lo ng as blinding is not jeopardized), including but not limited to the 
Invest igator’s Binde r, study drug, parti cipant m edical  records, inform ed consent docum entati on, 
and review of CRFs and associated source documents. It is important that the investigator and 
other study  personnel are available during the mo nitoring visit s and that sufficient t ime is devoted 
to the process.
12.2 Protocol Deviations
The invest igator should not deviate fro m the protocol , except where necessary  to eliminate an 
immediate hazard to studyparticipants. Shoul d other unexpected ci rcumstances arise that will 
requi re deviat ionfrom protocol -specified procedures, the invest igator should consult with the 
sponsor or designee (and IRB or IEC, as required) to determine the appropriate course of act ion. 
There will be no exempt ions (a prospectively approved deviat ion) from the inclusi on or exclusio n 
criteria.
Significant deviat ions include, but are not limited to, those that invo lve fraud or misconduct, 
increase the health risk to the participant, or confound interpretation of primary study assessment. 
12.3 Quality Assurance Audits and Reg ulatory Agency Inspections
The study  site also m ay be parti cipant to qualit y assurance audi ts by the Sponsor or designees. In 
this circumstance, the Sponsor -designated auditor will contact the site in advance to arrange an 
auditing visit. The auditor may a sk to vi sit the f acilities where laboratory  samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, inc luding 
those of foreign governments (eg, the FDA, the United Kingdo m Medicines and Healthcare 
products Regulatory  Agency , the Pharmaceut icals and Medical Devices Agency o f Japan). If the 
study  site is contacted for an inspect ion by a regulatory  body , the S ponsor should be notified 
immediately . The investi gator guarantees access for qualit y assurance auditors to all study  
docum ents as described in Sect ion 12.1.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 59of 88
Protocol Incorporating Amendment No. 01 11 March 2019
13.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the Int ernational Conference on Harminsat ion (ICH) Harmonised Tripartite 
Guideline for GCP. Each investigator will conduct the study  according to applicable local or 
regional regulatory  requi rements and align his or her conduct in accordance wit h the 
“Responsibil ities of the Investigator” that are listed in Appendix A. The principles of Helsinki are 
addressed through the protocol and through appendices contain ing requirements for informed 
consent and invest igator responsibilit ies.
13.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participat ing region. The Sponsor or designee will r equire documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this study , written notification regarding his or her abstinence fro m 
voting must also be obtaine d.Those Americas sites unwilling to provide names and tit les of all 
members due to privacy  and conflict of interest concerns should instead provide a Federal Wide 
Assurance Number or comparable number assigned by the Department of Health and Human 
Service s.
The Sponsor or designee will supply  relevant documents for submission to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Invest igator’s Brochure, a copy o f 
the ICF, and, if applicable, participant recruit ment materi als and/or advertisements and other 
docum ents requi red by all applicable l aws and regul ations, m ust be submitted to a central or local 
IRB or IEC for approval. The IRB’s or IEC’s written approval o f the protocol  and parti cipant 
inform ed consent m ust be obta ined and submitted to the Sponsor or designee before 
commencement of the study  (ie, before shipment of the Sponsor -supplied drug or study  specific 
screening activit y). The IRB or IEC approval must refer to the study  by exact protocol tit le, 
number, and ver sion date; i dentify versio ns of other documents (eg, ICF) reviewed; and state the 
approval  date. The Sponsor will ship drug/notify sit e once the Sponsor has confirmed the adequacy 
of site regulatory  docum entati on and, when applicable, the Sponsor has recei ved permissio n from 
competent authori ty to begin the study . Until the site receives drug/notificat ion no protocol 
activit ies, including screening, may occur.
Sites m ust adhere to all requirements stipulated by  their respect ive IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the ICF, recruit ment 
materi als intended for viewing by  parti cipants, l ocal safet y reporting requirements, reports and 
updates regarding the ongoing review of the study  at intervals sp
ecified by the respect ive IRB or 
IEC, and submissio n of the invest igator’s final status report to IRB or IEC. All IRB and IEC 
approval s and rel evant docum entati on for these i tems must be provi ded to the Sponsor or its 
designee.
Parti cipant incent ives shoul d not exert undue influence for participat ion. Payments to participants 
must be approved by the IRB or IEC and Sponsor.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 60of 88
Protocol Incorporating Amendment No. 01 11 March 2019
13.2 Participant Information, Informed Consent, and Participant Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The ICF, participant authorizat ion form (if applicable), and 
participant informat ion sheet (if applicable ) describe the planned and permitted uses, transfers, and 
disclosures of the parti cipant’s personal and personal healt h informat ion for purposes of 
conducting the study. The ICF and the participant informat ion sheet (if applicable) further explain 
the natu re of the study, its object ives, and potential risks and benefits, as well as the date informed 
consent is given. The ICF will detail the requirements of the participant and the fact that he or she 
is free to withdraw at any  time without giving a reason an d without prej udice to hi s or her further 
medical care.
The invest igator is responsible for the preparation, content, and IRB or IEC approval of the ICF 
and, if applicable, the participant authorizat ion form. The ICF, parti cipant authori zation form (if 
applicable), and participant informat ion sheet (if applicable) must be approved by both the IRB or 
IEC and the Sponsor prior to use.
The ICF, participant authorizat ion form (if applicable), and participant informat ion sheet (if 
applicable) must be written in a language fully comprehensible to the prospective participant. It is 
the responsibilit y of the invest igator to explain the detailed elements of the ICF, participant 
authori zation form (if applicable), and participant informat ion sheet (if applicable) to t he 
participant. Inform ation should be given in both oral and written form whenever possible and in 
the manner deemed appropriate by the IRB or IEC. In the event the participant is not capable of 
rendering adequate written informed consent, then the partici pant’s legally  acceptable 
representative may provide such consent for the participant in accordance with applicable laws and 
regul ations.
The parti cipant, or the participant’s legally acceptable representative, must be given ample 
opportunit y to: (1) inqui re about details o f the study, and (2) decide whether or not to participate in 
the study. If the participant, or the participant’s legally acceptable representative, determines he or 
she will participate in the study , then the ICF and participant authoriza tion form (if applicable) 
must be signed and dated by  the parti cipant, or the participant’s legally acceptable representative, 
at the time of consent and prior to the participant entering into the study . The parti cipant or the 
participant’s legally accepta ble representative should be instructed to sign using their legal names, 
not ni cknames, using blue or black ballpo int ink. The investigator must also sign and date the ICF 
and part icipant authorizat ion (if applicable) at the time of consent and prior to pa rticipant entering 
into the study; however, the Sponsor may allow a designee of the invest igator to sign to the extent 
permitted by  applicable law.
Once signed, the original ICF, participant authorization form (if applicable), and participant 
inform ation sheet (if applicable) will be stored in the invest igator’s site file. The invest igator must 
docum ent the date the participant signs the informed consent in the participant’s medical record. 
Copi es of the signed ICF, the signed participant authorizat ion form (if applicable), and participant 
inform ation sheet (if applicable) shall be given to the participant.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 61of 88
Protocol Incorporating Amendment No. 01 11 March 2019
All revised ICFs must be reviewed and signed by relevant participants or the relevant participant’s 
legally acceptable representative in the same manner as the original  informed consent. The date the 
revised consent was obtained should be recorded in the participant’s medical record, and the 
participant shoul d receive a copy  of the revised ICF.
Parti cipants who consented and provided a sample for DNA analy sis can wi thdraw thei r consent 
and request disposal o f a stored sample at any  time pri or to analysis. Notify Sponsor of consent 
withdrawal .
13.3 Participant Confidentiality
The Sponsor and designees affirm and upho ld the principle of the participant’s right to protection 
against invasio n of privacy. Throughout this study , a parti cipant’s source data will only be linked 
to the Sponsor’s clinical study  database or docum entati on via a unique ident ificat ion number. As 
permitted by all applicable laws and regulat ions, limited participant attributes, such as sex, age, or 
date of birth, and participant init ials may be used to verify the part icipant and accuracy  of the 
participant’s unique ident ification number.
To comply wit h ICH Guidelines for GCP and to verify co mpliance with this protocol, the Sponsor 
requi res the investigator to permit its monitor or designee’s monitor, representatives fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agen cy), the Sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the participant’s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and discharge s ummaries for hospi tal admissio ns occurring during a participant’s study  
participat ion, and autopsy  reports. Access to a participant’s original medical records requires the 
specific authorization of the participant as part of the inform ed consent process (s ee Section 13.2).
Copi es of  any parti cipant source documents that are provided to the Sponsor must have certain 
personally ident ifiable informat ion rem oved (ie, parti cipant nam e, address, and otherident ifier 
fields not collected on the participant’s CRF).
13.4 Publication, Disc losure, and Clinical Study Registration Policy
13.4.1 Publication and Disclosure
The invest igator is obliged to provide the Sponsor with complete test results and all data derived 
by the investigator from the study . During and after the study , only  the Sponsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as required by  
law or regul ation. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible web sites) rel ated to the protocol  or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibilit y of the Sponsor.
The Sponsor may publish any data and information fro m the study (including data and informat ion 
genera ted by  the invest igator) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prep ared in accordance with 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 62of 88
Protocol Incorporating Amendment No. 01 11 March 2019
this secti on and the Clinical Study  Site Agreement. In the event of any discrepancy  between the 
protocol  and the Clinical Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
13.4.2 Clinical Study Registration 
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, Takeda will, at a minimum register all 
intervent ional clinical trials it Sponsors anywhere in the world on Clini calTri als.gov and/or other 
publicly  accessible websites before start of study , as defined in Takeda Policy/Standard. Takeda 
contact informat ion, along wit h invest igator’s cit y, state (for Americas investigators), country, and 
recrui ting status will be regi stered and available for public viewing. 
For some registries, Takeda will assist callers in lo cating study  sites cl osest to thei r homes by 
provi ding the invest igator name, address, and phone number to the callers request ing study
inform ation. Once part icipants receive invest igator contact information, they may call thesite 
requesting enrollment into the study . The invest igative sites are encouraged to handle the study
inquiries according to their established participant screening process. If the caller as ks addi tional 
questions bey ond the topic of study enrollment, th ey shoul d be referred to the Sponsor.
Any investigator who objects to the Sponsor providing this informat ion to callers must provide the 
Sponsor with a written notice requesting that their inf ormation not be listed on the registry  site.
13.4.3 Clinical Study Results Disclosure 
Takeda will post the results of clinical trials on ClinicalTrials.gov or other publicly accessible 
websites, as required by Takeda Policy/Standard, applicable laws and/or regul ations.
13.5 Insurance and Compensation for Injury
Each participant in the study  must be insured in accordance with the regulat ions applicable to the 
site where the parti cipant is parti cipat ing. If a local underwriter is required, then the Sponsor or 
Sponsor’s designee will  obtain clinical  study  insurance against the risk of injury to study  
participants. Refer to the study  site agreement regarding the Sponsor’s policy on participant 
compensat ion and treatment for injury. If the investigator has questions regardi ng this po licy, he or 
she should contact the Sponsor or Sponsor’s designee.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK-954
Study ID TAK-954-1009 Page 63 of 88Protocol Incorporating Amendment No. 01 11 March 2019
14.0 ADMINISTRATIVE AND REFERENCE INFORMATION
14.1 Administrative Information
14.1.1 Study Contac t Information 
Contact Type / Role Contact
Serious adverse event and pregnancy reporting
Property of Takeda: For non-commercial use only and subject to the a le Terms of UseeTl
aPPD
TAK -954
Study ID TAK -954-1009 Page 64of 88
Protocol Incorporating Amendment No. 01 11 March 2019
14.1.2 Investigator Agreement 
I confirm that I have read and that I understand this protocol, the Invest igator’s Brochure, package 
insert and any other product informat ion provi ded by the Sponsor. I agree to conduct this study  in 
accordance with the requirements of this protocol and also to protect the rights, safet y, privacy, 
and well -being o f study participant s in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 (R2) Good Clinical Practice: Conso lidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requ irements for reporting serious adverse events defined in Sect ion10.2.9 of this 
protocol .
Terms outlined in the study  site agreement.
Responsibilit ies o f the Invest igator ( Appendix B).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contemplated in Appendix Cof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Title
Locati on of  Facilit y (Ci ty, State/Provence)
Locati on of  Facilit y (Country )
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 65of 88
Protocol Incorporating Amendment No. 01 11 March 2019
14.1.3 Study -Related Responsibilities 
The Sponsor will perform all study -related acti vities wi th the excepti on of  those i dentified in the 
Study -Related Responsibilit ies template . The vendors i dentified for specific study -related 
activit ies will perform these act ivities in full or in partnershi p with the Sponsor.
14.1.4 Protocol Amendment 01 Summary of Changes
Rationale for Amendment No. 01
The purpose of this amendment is to update the protocol to update the period of PD assessments 
(time to onset of defecation, number of stool per day, and stool form ) on Day  1 fro m predose only 
to following dosing on Day 1 until prior to dosing on Day 2, to allow assessment of the effect of the 
lead-in dose on GI transit. A clarificat ion was also made to indicate that stool will be collected and 
stool  form will be ass essed by the appropriate qualified clinic staff. 
In addit ion, the fo llowing changes were also applied:
Addit ion of postdose ECG and orthostatic vital signs measurements.
Removal of indicat ion for infusio n site assessments.
Correcti on of  discrepancy in the indicat ion in inclusion criteria #3 between Section 1.0Study  
Summary  (under Cri teria for Inclusio n) and Sect ion 7.1–Inclusio n Cri teria.
Correcti on of  discrepancy in the primary  endpoints between Sect ion 1.0–Study  Summary 
(under Main Criteria for Evaluat ion and Analysis) and Sect ion 5.3.1 –Primary Endpo ints.
Clarificat ion of the restrict ion peri od for alcoho l and x anthine and/or caffeine in Sect ion 7.3-
Excluded Medicat ions, Supplements, Dietary  Products .
Clarificat ion of the ar m fro m which blood sampling should be conducted during drug infusio n.
Update the PK sample co llection deviat ion window to include specific deviat ion windows to 
different postdose sampling t imes.
For specific descript ions of text changes and where the changes are located, see Appendix E.
14.1.5 List of Abbreviations
AE Adverse event
Ae Amount of drug excreted in urine
ALT Alanine aminotransferase
AUC Area under the concentration -time curve
AUClast Area under the concentration -time curve, from time 0 to the last observed non -zero 
concentration
AUC 0-24 Area under the concentration -time curve, from time 0 to the 24 -hour time point
AUC 0-inf Area under the concentratio n-time curve, from time 0 extrapolated to infinity
AV Atrioventricular
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 66of 88
Protocol Incorporating Amendment No. 01 11 March 2019
BMI Body mass index
bpm Beats per minute
Ceoi Concentration at end of infusion
CFR Code of Federal Regulations
CI Confidence interval
CL Clearance
CLR Renal clearance
cm Centimeter
Cmax Maximum observed concentration 
CPAP Clinical pharmacology analysis plan
CRF Case report form
CRU Clinical Research Unit
CYP Cytochrome P450
ECG Electrocardiogram
fe Fraction of IV dose excreted in urine 
g Gram
GCP Good Clinical Practice
GI Gastrointestinal
HBsAg Hepatitis B surface antigen
HCV Hepatitis C virus 
HIV Human immunodeficiency virus
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
IRB Institutio nal Review Board
IV Intravenous
kg Kilogram
LFT Liver function test
m2Meters squared
MedDRA®Medical Dictionary for Regulatory Activities®
mg Milligram
min Minute
mL Milliliter
mmHg Millimeter of mercury
msec Millisecond
MTD Maximum tolerated dose
NA Not applicable
ng Nanogram
P-gp P-glycoprotein
PD Pharmacodynamic(s)
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 67of 88
Protocol Incorporating Amendment No. 01 11 March 2019
pg Picogram
PK Pharmacokinetic(s)
QD Once daily
QTcF QT interval corrected for heart rate using Fridericia’s formula
SAE Serious adverse event
SAP Statistical analysis plan
SD Standard deviation
SUSARs Suspected unexpected serious adverse reactions
t½ Apparent first -order terminal elimination half -life
TEAE Treatment -emergent adverse event
ULN Upper limit of normal
US United States
USA United States of America
Vz Volume of distribution
WHO World Health Organization
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 68of 88
Protocol Incorporating Amendment No. 01 11 March 2019
15.0 DATA HANDLING AND RE CORDKEEPING
The full details of procedures for data handling will be documented in the Data Management Plan. 
AEs, medical history, and concurrent condit ions will be coded using the MedDRA®. Drugs will be 
coded using the WHO drug dict ionary.
15.1 CRFs (Electronic and/or Paper)
Com pleted CRFs are requi red for each participant who signs an informed consent.
Celeri on standard CRFs will be supplied. CRFs are produced, s tored electronically, and are 
available to the designated study team members. Each CRF is reviewed and signed by the PI. The 
final signed CRFs are provided to the Sponsor on CD.
After complet ion of the entry process, computer logic checks will be run to id entify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site. 
Correcti ons are recorded i n an audit trail that captures the old informat ion, the n ew inform ation, 
ident ificat ion of the person making the correction, the date the correction was made, and the reason 
for change. Reasons for significant corrections should addit ionally be included. 
The Invest igator must review the CRFs for completeness an d accuracy and must sign and date the 
appropriate CRFs as indicated. Furthermore, the investigator must retain full responsibilit y for the 
accuracy  and authent icity of all data entered on the CRFs.
After the lock of the clinical study database, any change of, modificat ion of, or addit ion to the data 
on the CRFs should be made by the investigator with use of change and modificat ion records of the 
CRFs. The Invest igator must review the data change for completeness and accuracy, and must sig n 
and date . 
CRFs w ill be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by study  monitors. The Sponsor or i ts desi gnee will  be permi tted to revi ew the parti cipant’s 
medical and hospital records pertinent to the study to ensure accuracy of the CRFs. The completed 
CRFs are the sole property  of the Sponsor and should not be made available in any  form to thi rd 
parties, except for authorized representatives of appropriate governmental health or regulatory  
authori
ties, wi thout wri tten permissi on of the Sponsor.
15.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 15.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing participants, medical records, temporary media such as therm al sensi tive paper, 
source worksheets, all original signed and dated ICFs, participant authorizat ion forms regarding 
the use of personal healt h information (if separate fro m the ICFs), el ectroni c copy  of CRFs, 
including the audit trail, and detailed record s of drug disposit ion to enable evaluat ions or audits 
from regulatory  authori ties, the Sponsor or i ts designees. Any  source documentati on printed on 
degradable thermal sensit ive paper should be photocopied by the site and filed wit h the original in 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 69of 88
Protocol Incorporating Amendment No. 01 11 March 2019
the par ticipant’s chart to ensure long -term legibili ty. Furtherm ore, ICH E6 Secti on 4.9.5 requires 
the investigator to retain essent ial docum ents specified in ICH E6 (Section 8) until at least 2 years 
after the last approval of a market ing applicat ion for a speci fied drug indicat ion being investigated 
or, if an applicat ion is not approved, until at least 2 years after the invest igation is discont inued and 
regul atory  authori ties are notifi ed. In addi tion, ICH E6 Secti on4.9.5 states that the study  records 
shoul d be retained unt il an amount of time specified by applicable regulatory requirements or for a 
time specified in the Clinical Study  Site Agreement between the investigator and Sponsor.
Refer to the Clinical Study  Site Agreement for the Sponsor’s requirements o n record retention. 
The invest igator and the head o f the inst itution shoul d contact and receive written approval from 
the Sponsor before disposing of any  such docum ents.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 70of 88
Protocol Incorporating Amendment No. 01 11 March 2019
16.0 REFERENCES
1.TAK -954. Millennium Pharmaceut icals, Inc. Global Invest igator Brochure. Edi tion 2.0, 
March 2018.
2.Lewis SJ, Heaton KW. Stool form scale as a useful guide to intest inal transit time. Scand J 
Gastroenterol. 1997 Sep;32(9):920 -4.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 71of 88
Protocol Incorporating Amendment No. 01 11 March 2019
17.0 APPENDICES
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 72of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Appendix AResponsibilities of the Investigator
Clinical research studies sponsored by  the Sponsor are participant to ICH GCP and all the 
applicable local laws and regul ations. The responsibilit ies imposed on investigators by  the FDA 
are summarized in the “Statement of Invest igator” (Form FDA 1572), whi ch m ust be com pleted 
and signed before the invest igator may participate in this study.
The invest igator agrees to assume the fo llowing responsibilit ies by signing a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2. Personally conduct or supervise the staff that will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to perform 
study -related duti es and funct ions, the invest igator/inst itution shoul d ensure that this 
individual or party  is qu
alified to perform those study -related duti es and functi ons and shoul d 
implement procedures to ensure the integrity  of the study -related duti es and funct ions 
perform ed and any  data generated.
4.Ensure that study  related procedures, including study  specific ( nonrouti ne/nonstandard panel) 
screening assessments are NOT performed on potent ial participants, pri or to the recei pt of  
written approval  from relevant governing bodies/authorities.
5.Ensure that all co lleagues and emplo yees assist ing in the conduct of the s tudy are informed of 
these obligat ions.
6.Secure prior approval o f the study and any changes by an appropriate IRB/IEC that conform to 
21 CFR Part 56, ICH, and local regulatory  requi rements.
7.Ensure that the IRB/IEC will be responsible for init ial review, con tinuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to participants. Make at least yearly reports on the progress of the study to the 
IRB/IEC, and issue a final report with in 3 months of study co mpletion.
8.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
regul ations, are m et.
9.Obtain valid informed consent from each participant who participates in the study , and 
docum ent the date of c onsent in the participant’s medical chart. Valid informed consent is the 
most current versi on approved by  the IRB/IEC. Each ICF should contain a participant 
authori zation sect ion that describes the uses and disclosures of a participant’s personal 
inform ation (including personal healt h informat ion) that will take place in connect ion wit h the 
study . If an ICF does not i nclude such a participant authorizat ion, then the invest igator must 
obtain a separate participant authorization form from each participant or the participant’s 
legally acceptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
CRFs, hospital records, laboratory  resul ts, etc, and maintain these data for a minimum of 
2years fo llowing n otificat ion by the Sponsor that all invest igations have been discont inued or 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 73of 88
Protocol Incorporating Amendment No. 01 11 March 2019
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
contact and receive written approval fro m the Sponsor before disposing o f any such 
documents.
11.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
12.Maintain current records of the receipt, administratio n, and disposit ion of Sponsor -supplied 
drugs, and return all unused Sponsor -supplied drug s to the Sponsor. 
13. Report adverse reactions to the Sponsor promptly. In the event of an SAE, notify the Sponsor 
within 24 hours.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 74of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Appendix BElements of the Participant Informed Consent
In seeking informed consent, the fo llowing informati on shall  be provi ded to each participant:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the participant’s participation.
4.A descript ion of the procedures to be fo llowed, in cluding invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of participants invo lved in the study .
7.A descript ion of the participant’s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the possible side effects of the treatment that the participant may receive.
11.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the participant and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the partici pant or to others that reasonably may  be expected 
from the research. When there is no intended clinical benefit to the participant, the pa rticipant 
shoul d be made aware of this.
13.Disclosures o f appropriate alternat ive procedures or courses of treatment, if any, that might be 
advantageous to the participant and their important potential risks and benefit s.
14.A statement describing the extent to which confident iality of records i dentifying the 
participant will be maintained, and a note of the possibilit y that regulatory agencies, auditor(s), 
IRB/IEC, and the monitor may inspect the records. By signing a written ICF, the participant or 
the particip ant’s legally  acceptable representative is authorizing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any  medical treatments are available if injury  occurs and, if 
so, what they  consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the participant for participat ing in the study.
17.The ant icipated expenses, if any , to the parti cipant for parti cipating in the study .
18.An e xplanat ion of whom to contact for answers to pertinent questions about the research 
(invest igator), participant’s rights, and IRB/IEC and whom to contact in the event of a 
research -related inj ury to the parti cipant.
19.A statement that participation is vo luntary, that refusal to participate will invo lve no penalt y or 
loss of benefit s to whi ch the parti cipant otherwi se is ent itled, and that the participant or the 
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 75of 88
Protocol Incorporating Amendment No. 01 11 March 2019
participant’s l egally acceptable representative may discont inue participat ion at any  time 
without p enalt y or loss of benefit s to whi ch the parti cipant is otherwise ent itled.
20.The consequences o f a participant’s decisio n to withdraw fro m the research and procedures for 
orderly terminat ion of part icipation by the participant.
21.A statement that the participa nt or the participant’s legally  acceptable representative will be 
inform ed in a t imely manner if informat ion beco mes available that may be relevant to the 
participant’s willingness to continue participation in the study .
22.A statement that results of DNA ana lysis will not be disclo sed to an individual, unless 
prevailing laws require the Sponsor to do so.
23.The foreseeable circumstances or reasons under which the participant’s participat ion in the 
study  may be terminated.
24.A written partici pant authori zation (either contained within the ICF or provided as a separate 
docum ent) describing to the participant the contemplated and permissible uses and disclosures 
of the participant’s personal informat ion (including personal health informat ion) for purposes 
of conductin g the study . The parti cipant authori zation must contain the following statements 
regarding the uses and disclo sures of the participant’s personal information:
a)that personal information (including personal healt h informat ion) may be processed by  or 
transfer red to other parties in other countries for clinical research and safet y reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assist ing Takeda, its affiliates, and li censing 
partners; (3) regulatory  agencies and other healt h authorities; and (4) IRBs/IECs;
b)it is possible that personal informat ion (including personal healt h informat ion) may be 
processed and transferred to countries that do not have data protection laws that offer 
participants the sam e level  of protecti on as the data protection laws wit hin this country; 
however, Takeda will make every  effort to keep y our personal  information confident ial, 
and y our name will not be di sclosed outsi de the clinic unless requi red by law;
c)that personal information (including personal healt h informat ion) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safet y and effect iveness o f the study  medicat ion(s), studying other therapies for pati ents, 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies;
d)that participants agree not to restrict the use and disclosure of their personal information 
(including personal healt h informat ion) upon withdrawal  from the study  to the extent that 
the restricted use or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
e)that the participant’s ident ity will remain confidential in the event that study  resul ts are 
publishe d.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 76of 88
Protocol Incorporating Amendment No. 01 11 March 2019
25.Female participants of childbearing potential (eg, nonsterilized, premenopausal female 
participants) who are sexually active must use highly effect ive contraception (as defined in the 
inform ed consent) from signing the informed consent and throughout the duration of the study, 
and for 30 days after the last dose of study  drug. Regul ar pregnancy  tests will be performed 
throughout the study  for all female part icipants of childbearing potential. If a participant is 
found to be pregnant during study , study  drug will  be discont inued and the invest igator will 
offer the participant the choice to receive unblinded treatment informat ion. 
26.Male participants must use highly effective contraception (as defined in the informed consent) 
from signing the informed consen t throughout the duration of the study  and f or 90 day s after 
the last dose of study  drug. If the partner of the participant is found to be pregnant during the 
study , the invest igator will offer the participant the cho ice to receive unblinded treatment 
information. 
27.A statement that clinical trial informat ion from this study  will be publicly disclosed in a 
publicly  accessible website, such as ClinicalTrials.gov.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 77of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Appendix CInvestigator Consent to the Use of Personal Information
Takeda will co llect and retain personal information of invest igator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, invest igator’s personal 
inform ation may be transferred to other parties located in countri es throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and licensing partners.
Regulatory  agencies and other h ealth authori ties.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies tha t may contain 
the sam e chemical com pound present in the study  medicat ion.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiving an d audi t of study  records.
Posting investigator site contact informat ion, study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 78of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Appendix DPregnancy and Contraception
Contraception and Pregnancy Avoidance Procedure 
Animal studies for TAK -954 have dem onstrated embry otoxi city and there i s a lack of  adequate 
reproducti ve toxi city data in humans. Given that TAK -954 di d not exhibit genotoxic potential in 
the standard battery  of genotoxi city assays and the terminal disposit ion phase half -life of 
TAK -954, the durati on of  contracepti on for 30 days i s considered acceptable. This is in line wit h
the Clinical Trials Facilitat ion Group “Reco mmendations related to contraception and pregnancy 
testing in clinical trials” [CTFG, 2014] .
Females of reproductive potential, as well as fertile men and their partners who are female of 
reproducti ve potenti al, m ust agree to abstain fro m sexual intercourse or to use 2 highly  effect ive 
forms of contraception from the time o f giving info rmed consent, during the study, and for 30 days 
(females and males) fo llowing the last dose of study  drug. An effective form of contraception is 
defined as hormonal oral contraceptives, injectables, patches, intrauterine devices, double -barrier 
method (eg, synthet ic condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel) 
or male partner st erilizat ion.
The follow ing definitions apply for contraception and pregnancy avoidance procedures:
A wo man is considered a woman of childbearing potential (fertile) fo llowing menarche and unt il 
beco ming postmenopausal unless permanent ly sterile. Permanent sterilizat ion methods include 
hysterectomy and bilateral oophorectomy . A postmenopausal state is defined as no menses for 
12months wi thout an al ternat ive medical cause.
Sterilized males should be at least 1 y ear postbilateral  vasectomy and have confirmed that they  
have obtained documentation of the absence of sperm in the ejaculate or have had bilateral 
orchi dectomy .
Pregnancy
If any subject is confirmed to be pregnant during the study, she should be withdrawn and TAK -954 
shoul d be immediately discont inued . In addi tion, any  pregnancies in the partner of a male subject 
during the study  or for 30 day s after the l ast dose should also be recorded fo llowing authori zation 
from the subject’s partner. A pregnancy  notificat ion form shoul d be submitted within 24 hour s of 
learning of the pregnancy.
If the female subject and/or female partner of a male subject agree to the primary  care physician 
being informed, the invest igator should notify the primary care physician that the female 
subject/female partner of the subjec t was parti cipating in a clinical study  at the time she became 
pregnant and provide details o f the study  drug the subject received.
All pregnancies, including female partners of male subjects, in subjects on active study  drug will  
be fo llowed up to final o utcom e using the pregnancy form. The outcome, including any premature 
termination, must be reported to the Sponsor. An evaluat ion after the birth of the child will also be 
conducted.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 79of 88
Protocol Incorporating Amendment No. 01 11 March 2019
The follow ing procedures apply for contraception and pregnancy avoidance.
Highly effect ive methods of contraception are defined as “those, alone or in co mbinat ion, that 
resul t in a l ow failure rate (i e, less than 1% failure rate per y ear when used consistent ly and 
correctly ). In this study , where m edicat ions and devices contain ing horm ones are included, the 
only acceptable methods of contraception are:
Non-Hormonal Methods: 
–Intrauterine device (IUD).
–Bilateral tubal occlusio n.
–Vasectomised partner (provided that partner is the sole sexual partner of the study  
participant and th at the vasectomised partner has received medical assessment of the 
surgi cal success).
–True sexual abstinence, only if this is in line wit h the preferred and usual lifest yle of the 
participant. True abstinence is defined as refraining from heterosexual inte rcourse during 
the ent ire peri od of  the study , from 1 month pri or to the first dose until 30 days after last 
dose.
Horm onal Methods: Horm onal contracepti on m ay be suscept ible to interaction with the 
investigat ive co mpound, comparator, concomitant medicat ions, which may reduce the efficacy 
of the contraception method (Evaluate on compound -by-compound and protocol –by-protocol 
basis and obtain clinical pharmaco logy justificat ion).
–Combined (estrogen and progestogen) hormonal contraception associated with inhi bition 
of ovul ation initiated at least 3 months prior to the first dose of study  drug OR combined 
with a barrier method (male condo m, female condom or diaphragm) if for shorter duration 
until she has been on contraceptive for 3 months;
Oral.
Intravaginal ( eg, ring).
transderm al.
–Progestogen -only hormonal contracepti on associ ated wi th inhibit ion of ovulation1 
initiated at least 3 months prior tothe first dose of study  drug OR combined with a 
barrier method (male condo m, female condo m or diaphragm) if shorte r till she has bee n 
on contraceptive for 3 months;
oral.
Injectable.
Implantable.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 80of 88
Protocol Incorporating Amendment No. 01 11 March 2019
28. E ffective methods of contracepti on (there m ay be a higher than 1% failure rate) are: 
Doubl e-barrier method (contraceptive sponge, diaphragm or cervical cap wit h spermicidal 
jellies or creams PLUS male condo m).
Progestogen only hormonal contraception, where inhibit ion of ovulat ion is not the primary 
mode of act ion PLUS condom wit h or without spermicide.
29.Unacceptable methods of contraception are:
Periodic abst inence (eg, calend ar, ovul ation, symptothermal, post -ovulation methods).
Spermicides only .
Withdrawal.
No m ethod at all.
Use of female and male condoms together.
Cap/di aphragm/sponge wi thout spermicide and wit hout condom .
Reference:
Clinical Trials Facilitat ion Group , Recom mendati ons related to contraception and pregnancy 
testing in clinical trials . Sep 2014.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 81of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Appendix EDetailed Description of Amendments to Text
Change 1. Update collection period of  PD measurements on Day  1 fro mpredose on Day  1 to 
following dosing on Day  1 through pri or to dosing on Day  2.
The primary change occurs in Secti on 1.0–Study  Summary , under Study Design (last sentence in
the fourth paragraph) and in Section 6.1–Study  Design (l ast sentence in the fourth paragraph).
Initial 
wording:The time to first stool will be recorded postdose on Day  2 and number of stools per 
day and stool form (Bristol Stool Form Scale) will be recorded for 36 hours postdose 
on Day  2.
Amended 
or new 
wording:The time to first stool will be recorded following dosing on Day 1 until pri or to 
dosing on Day 2 and following dosing on Day 2. The number of stools per day  and 
stool  form (Bristol Stool  Form Scale) will be recorded following dosing on Day  1 
until prior to dosing on Day 2 and for 36 hours following Day 2dosing .
Rationale for Change:
Extend the collection time for PD measurements on Day 1 to allow the assessment of the effect of 
the lead -in dose on GI transit time.
Other Sections Affected:
Secti on 3.1–Screening and Period 1 and Section 3.2–Periods 2 and 3 (under Section 3.0-
Schedule of Study  Procedures) .
Initial 
wording:
(…)Study Period 
(…)Day 1 Day 2
Hours relative to start of infusion on 
Day 1Hours 
relative to 
start of 
infusion 
on Day 2
Predose 0 1 1.083 1.25 3 9 Predose
Pharmacodynamic Evaluations
Time to O nset of Defecation X
Number of S tools per Day X
Stool Form (Bristol Stool Form 
Scale)X
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 82of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Amended or 
new 
wording:
(…)Study Period 
(…)Day 1 Day 2
Hours relative to start of infusion on Day 1 Hours 
relative 
to start 
of 
infusion 
on Day 2
Predose 0 1 1.083 1.25 3 9 Predose
Pharmacodynamic Evaluations
Time to O nset of Defecation X  -------------   Continuous  ------------ X
Number of S tools per Day X  ---------------   Continuous  ---------- X
Stool Form (Bristol Stool Form 
Scale)X  -------- ------   Continuous  ---------- -X
Secti on 9.3.2 –PD measurements
Initial 
wording:The fo llowing param eters derived after TAK -954 administration on Day  2 of each 
treatm ent peri od will be assessed:
Amended or 
new 
wording:The fo llowing param eters derived following dosing on Day 1 unt il prior to Day 2 
dosing and fo llowing dosing on Day  2 of each treatm ent peri od will be assessed:
Change 2. Addit ion of text to indicate that stool  samples will be co llected and stool form will be 
assessed by the appropriate qualified clinic staff, and that stool samples will not be stored and will 
be discarded fo llowing the recording of PD evaluatio ns.
The primary  change occurs in Section 9.3.2 –PD Measurements.
Amended 
or new 
wording:The time to first stool and number of stools per day will be recorded . Stool samples 
will be co llected and stool form (Bristol  Stool  Form  Scale) will be assessed by  the 
appropriate qualified clinic staff. Stool  samples will not be stored and will be 
discarded foll owing the recording of PD evaluations.
Rationale for Change: 
Clarifies the stool  collect ion, form  assessment, and sample handling processes.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 83of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Change 3. Update of the PD analysis language to clarify that stool form assessments results will be 
listed, and no summary  statist ics will be conducted .
The primary  change occurs in Section 11.1.5 -PD Analysis.
Initial 
wording:Descript ive statistics will be provided for time to first stool, number of stools per 
day, and stool  form using appropri ate summary statist ics to be fully specified in the 
SAP.
Stool  form (using Bristol  Stool  Form  Scale [ Lewis SJ, Heaton KW, 1997 ]) will be 
summarized by  treatm ent and point of time of collection.
Amended 
or new 
wording:Descript ive statist ics will be provided for time to first stool and number of sto ols per 
day using appropri ate summary statist ics to be fully  specified i n the SAP.
Stool  form (using Bristol  Stool  Form  Scale [ Lewis SJ, Heaton KW, 1997 ]) will be
listed.
Rationale for Change: 
Due to the qualitat ive nature of the stool form assessment, summary statist ics will not provide an 
added value for data interpretation.
Change 4. Addit ion of postdose ECG and orthostatic vital signs measurements.
The primary change occurs in Sect ions3.1-Screening and Period 1 and Section 3.2–Periods 2 and 
3.
Initial 
wording:
(…)Study Period 
Day
1Day
2Day
3
Hours relative to start of infusion 
on Day 1 Hours relative to start of infusion on Day 2
Pre
dose 0 1 1.083 1.25 3 9Pre
dose 00.5 1 2 4 6 12 24 36
12-Lead ECG X X
Orthostatic Vital 
Signs (HR, BP)X XX X X
Study Period 
Day 8 Day 10 Day 12 Day 14 Day 16
Hours relative to start of infusion on Day 2
144 192 240 288 336
Orthostatic Vital Signs (HR, BP) X X X X
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 84of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Amended 
or new 
wording:
(…)Study Period 1 b
Day
1Day
2Day
3
Hours relative to start of infusion 
on Day 1 Hours relative to start of infusion on Day 2
Pre
dose 0 1 1.083 1.25 3 9Pre
dose 00.5 1 2 4 6 12 24 36
12-Lead ECG X X X X XX X X
Orthostatic Vital 
Signs (HR, BP)X X X XX X X
Study Period 
Day 8 Day 10 Day 12 Day 14 Day 16
Hours relative to start of infusion on Day 2
144 192 240 288 336
12-Lead ECG X X X X
Orthostatic Vital Signs (HR, BP) X X X X
Rationale for Change: 
ECG and orthostatic vital signs measurements were added to improve the subjects’ safet y.
Other Sections Affected:
Secti on 9.2.5 - 12- Lead ECG (sentence added to the last paragraph).
Initial 
wording:ECGs will be measured prior to Day 1 dosing of each period for the predose time 
point. At all other predose time points v ital signs will  be measured wi thin 2 hours 
prior to dosing.
Amended 
or new 
wording:ECGs will be measured prior to Day 1 dosing of each period for the predose time 
point. At all other predose time points vital signs will be measured within 2 hours 
prior to dosing. When scheduled postdose, ECGs will be performed wit hin 
approximately  20minutes of the scheduled time point.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 85of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Change 5. Rem oval of indicat ion for infusi on si te assessments.
The primary  change occurs in Section 9.2.6 –Infusion Site Evaluat ion.
Initial 
wording:9.2.6 – Infusio n Site Reacti on
In monitoring AEs, special attention will be paid to potential infusion site reactions 
(ie, local tolerabili ty). Infusi on site reacti ons will be evaluated as outlined in the 
Schedule of Study  Procedures (Section 3.0) and any abnormal findings will be 
reported as AEs.
Amended 
or new 
wording:(secti on rem oved)
Rationale for Change: 
Infusio n site reaction will be assessed as part of AE monitoring and not at schedule time po ints. As 
such, the section was removed.
Other Sections Affected:
Secti on 1.0–Study  Summary, under Study  Design ( firstsentence in the fourth paragraph) and 
Secti on 6.1–Study  Design ( firstsentence in the fourth paragraph) .
Initial 
wording:Safety will be assessed by monitoring for adverse events (AEs), vital signs, 
orthostatic vital signs, electrocardiograms (ECGs), infusio n site assessment, safet y 
laboratory  assessments, and physical examinat ions throughout each dosing period.
Amended 
or new 
wording:Safety will be assessed by monitoring for adverse events (AEs), vital signs, 
orthostati c vital signs, el ectrocardi ograms (ECGs), safet y laboratory  assessments, 
and physical examinat ions throughout each dosing period .
Change 6. Correction of discrepancy in Inclusio n criteria #3 between Section 1.0–Study  
Summary  (under Criteria for Inclusio n) and Sect ion 7.1–Inclusio n Cri teria.
The primary  change occurs in Secti on 7.1–Inclusion criteria .
Initial 
wording:Medically  healthy wi th no clinically  significant m edical history , physical 
examinat ion, laboratory profiles, vital signs or ECGs, as deemed by the Invest igator 
or desi gnee.
Amended 
or new 
wording:Medically  healthy wi th no clinically  significant m edical history , physical 
examinat ion, laboratory  profiles, vital signs , orth ostati c vital signs, or ECGs, a s 
deem ed by  the Invest igator or designee.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 86of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Rationale for Change: 
Orthostatic vital signs are assessed as part eligibility assessments at screening and as such, the 
indicat ion for orthostatic vital signs was added to Inclusion criteria #3 in Sect ion 7.1–Inclusio n 
criteria to correct the discrepancy  with the correct indicat ion in Sect ion 1.0–Study  Summary  
(under Criteria for Incl usion). 
Change 7. Rem oval of physical examinat ion from the primary  endpoints in Sect ion 1.0–Study  
Summary  (under Main Criteria for Evaluation and Analysis) to correct a discrepancy wit h 
Secti on5.3.1 –Primary Endpoints.
The primary  change occurs in Secti on 7.1–Inclusion criteria .
Initial 
wording:The fo llowing safety parameters of TAK -954 derived after a single dose of 
TAK -954 on Day  2 of each treatm ent peri od:
Treatment emergent AE (TEAE) assessments.
Vital signs.
12-lead ECG.
Clinical laboratory  testing (hematol ogy, serum  chemistry  and urinalysis).
Physical Examinat ions
Amended 
or new 
wording:The following safety parameters of TAK -954 derived after a single dose of 
TAK -954 on Day  2 of each treatm ent peri od:
Treatment emergent AE (TEAE) assessments.
Vital signs.
12-lead ECG.
Clinical laboratory  testing (hematol ogy, serum  chemistry  and urinalysis).
Rationale for Change: 
Physical examinat ions are assessed as during the study  but are not considered a primary  endpoint 
and as such, was removed from the primary  endpoints in Secti on 1.0–Study  Summary  (under 
Main Criteria for Evaluat ion and Analys is) to correct the discrepancy with the correct indicat ion in 
Secti on5.3.1 –Primary Endpoints.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 87of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Change 8. Clarificat ion of restrict ion peri od for alcohol  and x anthine and/or caffeine
post-randomizat ion (Day  1) to Foll ow-up.
The primary change occurs in Section 7.3-Excluded Medicat ions, Supplements, Dietary Products
(under Table 7.a).
Initial 
wording:Category
(…)Post-Randomization (Day 1) to Follow -Up 
Alcohol Prohibited in each period and throughout the period of PK 
sample collection in each Treatment period.
Xanthine and/or 
caffeineProhibited in each period and throughout the period of PK 
sample collection in each Treatment period.
Amended 
or new 
wording:Category
(…)Post-Randomization (Day 1) to Follow -Up 
Alcohol Prohibited from 48 hours prio r to first dosing in each 
period and throughout the period of PK sample collection 
in each Treatment period.
Xanthine and/or 
caffeineProhibited from 24 hours prio r to first dosing in each 
period and throughout the period of PK sample collection 
in each Treatment period.
Rationale for Change: 
Clarify  that the restri ction peri od pri or to fi rst dose (i .e. 48 hours for alcoho l and 24 hours for 
xanthine and/or caffeine) is applicable to each study period.
Change 9. Addit ion of language to clarify that d uring infusio n, blood sam ples shoul d be co llected 
from the contral ateral arm opposi te the infusio n site.
The primary  change occurs in Secti on 9.2-Clinical Procedures and Assessments (second 
paragraph) .
Initial 
wording:For thi s study , safet y, tolerabili ty and the collect ion of blood for plasma 
concentrations for TAK -954 i s a cri tical parameter and are required to be collected 
as close to the scheduled times defined in this protocol as possible. All other 
procedures should be completed as close to the prescribed/scheduled time as 
possible, but can be performed prior or after the prescri bed/scheduled t ime.
Amended 
or new 
wording:For thi s study , safet y, tolerabili ty and the collect ion of blood for plasma 
concentrations for TAK -954 i s a cri tical parameter and are required to be collected 
as close to the scheduled times defined in this pro tocol  as possible. During infusio n, 
blood sam ples shoul d be collected from  the contralateral arm opposi te the infusio n 
site. All other procedures should be completed as close to the prescribed/scheduled 
time as possible, but can be performed prior or after the prescribed/scheduled time.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

TAK -954
Study ID TAK -954-1009 Page 88of 88
Protocol Incorporating Amendment No. 01 11 March 2019
Rationale for Change: 
For consistency in blood sample co llection, it is clarified that d uring infusio n, blood sam ples 
shoul d be collected from  the contralateral arm opposi te the infusio n site .
Change 10.Removal of the general deviat ion window (10%) for PK sampling with a table that 
includes different and more strict deviat ion windows based on the nominal sampling time.
The primary  change occurs in Secti on 9.3.1.1 -Plasma f or PK Measurements (last paragraph) .
Initial 
wording:Other PK parameters may  be calculated, if deemed necessary , for the interpretati on 
of the data. All efforts will be made to obtain the PK samples at the exact nominal 
time rel ative to dosing. However, samples obtained within 10% of the nominal t ime 
from dosing will not be captured as a protocol deviation, as long as the exact time of 
dosing and the sample collection is noted on CRF.
Amended
or new 
wording:Other PK parameters may  be calculated, if deemed necessary , for the interpretati on 
of the data. All efforts will be made to obtain the PK samples at the exact nominal 
time rel ative to dosing. Ho wever, samples obtained within the time windo ws 
indicated in Table 9.cwill not be captured as a protocol deviation, as lo ng as the 
exact time of dosing and the sample co llection is noted on CRF .
Table 9.c Pharmaco kinetics Sample Collection Time Window
Time window (m inutes ) Nominal Sample Time
Up to 30 minutes prior to dose Predose
±2 Immediately post start of infusion to 1.25 hours
±5 >1.25 hours to 6 hours
±10 >6 hours to 36 hours
±30 >36 hours
Rationale for Change: 
Clarify  and ti ghten the allowed deviation window for sample collection to guaranty  a closer 
associ ation between the no minal and actual sampling time.
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

䢢
䢢䢢䢢
䢢
䢢䢢
䢢
(/(&7521,& 6,*1$785(6 
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 

  

  

  


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


GDDE䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢲䢳䢢䢯䢢䣃䢢䣒䣪䣣䣵䣧䢢䢳䢮䢢䣔䣣䣰䣦䣱䣯䣫䣼䣧䣦䢮䢢䣆䣱䣷䣤䣮䣧䢯䣄䣮䣫䣰䣦䢮䢢䣒䣮䣣䣥䣧䣤䣱䢯䣅䣱䣰 䣶䣴䣱䣮䣮䣧䣦䢮䢢䣕䣫䣰䣩䣮䣧䢢䣃䣵䣥䣧䣰䣦䣫䣰䣩䢢䣆䣱䣵䣧䢮䢢䢵䢢䣒䣧䣴䣫䣱䣦䢮
䣋䣰䣥䣱䣯䣲䣮䣧䣶䣧䢢䣄䣮䣱䣥䣭䢢䣆䣧䣵䣫䣩䣰䢢䣕䣶䣷䣦䣻䢢䣶䣱䢢䣋䣰䣸䣧䣵䣶䣫䣩䣣䣶䣧䢢䣶䣪䣧䢢䣕䣣䣨䣧䣶䣻䢮䢢䣖䣱䣮䣧䣴䣣 䣤䣫䣮䣫䣶䣻䢮䢢䣒䣪䣣䣴䣯䣣䣥䣱䣭䣫䣰䣧䣶䣫䣥䣵䢢䣣䣰䣦䢢䣒䣪䣣䣴䣯䣣䣥䣱䣦䣻䣰䣣䣯䣫䣥䣵
䣱䣨䢢䣖䣃䣍䢢䢻䢷䢶䢢䣫䣰䢢䣊䣧䣣䣮䣶䣪䣻䢢䣃䣦䣷䣮䣶䢢䣒䣣䣴䣶䣫䣥䣫䣲䣣䣰䣶䣵䢰
%LRVWDWLVWLFV$SSURYDO 0DU87&
&OLQLFDO6FLHQFH$SSURYDO 0DU87&
&OLQLFDO3KDUPDFRORJ\$SSURYDO 0DU87&
Property of Takeda: For non-commercial use only and subject to the applicable Terms of Useble Tate ate 
ablHH:mm ‘UH:mm eT
ab87&87&

0DU0DUPPD